

**A DISSERTATION ON  
USE OF PULSE OXIMETRY SCREENING  
IN EARLY DETECTION OF  
CONGENITAL HEART DISEASE**

**M.D (BRANCH VII)  
PAEDIATRIC MEDICINE  
APRIL 2012**



**THE TAMILNADU  
DR.MGR.MEDICAL UNIVERSITY  
CHENNAI, TAMILNADU**

## **CERTIFICATE**

This is to certify that the dissertation entitled “**USE OF PULSE OXIMETRY SCREENING IN EARLY DETECTION OF CONGENITAL HEART DISEASE**” submitted by **Dr. V. EZHIL SRINIVASAN** to the Faculty of Paediatrics, The Tamil Nadu Dr. M.G.R. Medical University, Chennai in partial fulfillment of the requirement for the award of M.D. Degree Branch VII (Paediatrics) is a bonafied research work carried out by him under our direct supervision and guidance.

**Prof. Dr.S. Sambath, M.D.,DCH.,**

**Professor of Paediatrics,  
Institute of Child Health &  
Research Centre,  
Madurai Medical College,  
Madurai.**

**Prof. Dr.P.Amutha Rajeshwari,  
M.D.,DCH.,**

**Director,  
Institute of Child Health &  
Research Centre,  
Madurai Medical College,  
Madurai.**

## **DECLARATION**

I, **Dr.V. EZHIL SRINIVASAN** solemnly declare that the dissertation titled “**USE OF PULSE OXIMETRY SCREENING IN EARLY DETECTION OF CONGENITAL HEART DISEASE**” has been prepared by me.

This is submitted to the **Tamilnadu Dr.M.G.R.Medical University**, Chennai in partial fulfillment of the rules and regulations for the M.D.Degree Examination in Paediatrics.

Place: Madurai

Date:

**Dr. V. EZHIL SRINIVASAN**

## ACKNOWLEDGEMENT

I thank the **DEAN**, Madurai Medical College and Government Rajaji Hospital Madurai for permitting me to perform this study.

It is with immense pleasure and privilege that I express my heartfelt gratitude, admiration and sincere thanks to **Prof. Dr. P. Amutha Rajeshwari, M.D., D.C.H.**, Director, Institute of Child Health, Govt. Rajaji Hospital, for her guidance and support during this study.

I express my sincere thanks and heartfelt gratitude to my chief **Prof. Dr. S. Sambath, M.D., D.C.H.**, for his support, guidance, supervision and constant encouragement throughout this study.

I express my sincere thanks to **Prof. Dr. Mathevan, M.D., D.C.H.**, **Prof. Dr. Chitra Ayappan, M.D., D.C.H.**, for their guidance and encouragement throughout the study.

I also express my thanks to **Prof. Dr. Sankara subramaniam, M.D., D.C.H.**, **Prof. Dr. Nagendran, M.D., D.C.H.**, **Prof. Dr. S. Venkateswaran, M.D., D.C.H.**, for their guidance and encouragement throughout this study.

I express my sincere thanks to **Dr.R.A.JANARTHANAN, M.D., D.M**, Professor and Head of Department of Cardiology for

permitting me to utilize the facilities in the Department for the purpose of this study and guiding me with enthusiasm throughout the study period.

I would like to thank Registrar **Dr. M. Kulandaivel, M.D., D.C.H.**, for his valuable suggestion throughout the study.

I wish to express my sincere thanks to my guide and teacher, Asst professor **Dr.S. Shanmuga Sundaram, M.D., D.C.H.**, and **Dr. E. Sivakumar, M.D.**, for their valuable suggestion, support and guidance at every stage of this study.

I also thank all the members of the Dissertation Committee for their guidance during the study.

I thank the members of the Ethical Committee, Government Rajaji Hospital and Madurai Medical College, Madurai for permitting me to perform this study.

I also express my gratitude to all my fellow post graduates for their kind cooperation in carrying out this study and for their critical analysis.

I thank all the parents and babies without whom this study would not have been possible.

## CONTENTS

| SL.NO | TITLE                   | PAGE NO. |
|-------|-------------------------|----------|
| 1.    | Introduction            | 1        |
| 2.    | Review of Literature    | 3        |
| 3.    | Aim and Objectives      | 36       |
| 4.    | Materials and Methods   | 37       |
| 5.    | Observation and Results | 41       |
| 6.    | Discussion              | 52       |
| 7.    | Conclusion              | 64       |
| 8     | Limitations             | 65       |
| 9.    | Recommendations         | 66       |
| 10.   | Bibliography            |          |
| 11.   | Proforma                |          |
| 12.   | Master chart            |          |
| 13.   | Abbreviations           |          |

## INTRODUCTION

Among all congenital malformations, congenital heart disease is a relatively common problem with an incidence of 5-8 in every 1000 live births<sup>1-9</sup>. Of this 25% will have critical congenital heart disease.<sup>9-12</sup> Congenital heart disease account for about 10% of infant deaths and about half of deaths due to congenital malformations in developed countries<sup>2</sup>. Now a days even complex congenital heart disease can be treated with the appropriate surgical or catheter intervention<sup>13</sup>. Early diagnosis of congenital heart disease is important for a good clinical outcome. Unrecognized or delayed diagnosis of some severe congenital heart diseases can lead to cardiac failure, cardiovascular collapse, and even death<sup>14-18</sup>.

However diagnosis of congenital heart disease in the first few days of life is difficult because of an initial lack of specific clinical signs<sup>2</sup>. Clinical examination remains the most frequently used method to diagnose congenital heart disease in new borns<sup>19-22</sup>. In particular the presence of a heart murmur can raise the suspicion of congenital heart disease. But routine neonatal clinical examination fails to detect more than 50% of infants with congenital heart disease<sup>23</sup>. More than 55% of them have no murmur<sup>24</sup> and most of them are discharged before a

diagnosis can be made and readmitted with severe heart failure or cardiovascular collapse<sup>23</sup>.

Therefore there is a need for effective screening program for early detection of congenital heart disease. This disease would be ideally suited for a screening program if simple and reliable method were available. Recently pulse oximetry has been suggested as a screening tool for detection of congenital heart disease especially cyanotic and critical congenital heart diseases in asymptomatic new born.<sup>10,11,26</sup> These babies have a decreased oxygen saturation due to right to left shunt which is either intracardiac or at Patent ductus arteriosus (PDA) level. This can be measured by pulse oximetry.



# **REVIEW OF LITERATURE**

## **CARDIAC DEVELOPMENT**

Knowledge of the mechanisms of cardiac development is necessary in understanding congenital heart defects and developing strategies for prevention.


## **EARLY CARDIAC MORPHOGENESIS**

The fetal heart is morphologically developed at 8<sup>th</sup> week of gestation<sup>5,28</sup>. First identifiable cardiac precursors are angiogenic cell clusters arranged on both sides of the embryos central axis. These clusters form paired cardiac tube by 18 days of gestation. The paired tubes fuse in the mid line on the ventral surface of the embryo to form the primitive heart tube by 22 days. As early as 20-22 days, before cardiac looping, the embryonic heart begins to contract and exhibits phases of the cardiac cycle that are surprisingly similar to those of in a mature heart<sup>29</sup>. Morphologist have identified segments of the heart tube that were believed to correspond to structures in a mature heart, the sinus venosus and atrium (right and left atria), the primitive ventricle (left ventricle), the bulbus cordis (right ventricle) and the truncus arteriosus (aorta and pulmonary artery).

## **CARDIAC LOOPING**

Between day 23-28 the heart tube is making a loop to the right moving the atrial portion cranially, the ventricular part caudally and the out flow tract remains positioned cranially<sup>30</sup>. When something goes wrong at this stage, the results can be a physiologically corrected transposition of the great arteries or an incorrect relation between the left atrium and aorta causing an AV plane displacement resulting in a double inlet left ventricle or a double outlet right ventricle.

The normal asymmetry caused by the rightward rotation determines the situs of the fetus and normal situs is called situs solitus. If the normal asymmetry does not occur, the result can be situs inversus (mirror image of the normal atrial relationship), situs ambiguous or left or right atrial isomerism (bilateral left sided or bilateral right sided atria).<sup>29</sup>



**TIMELINE. FORMATION OF THE HEART.**

The chamber differentiation then occurs between days 27-37 and can be divided into four parts beginning with the development of aortic arches. There are originally 6 paired branchial arches developed. They form at different times and regress in a complex way. The first one develops further to become vessels in the face and carotid arteries. Only the 6<sup>th</sup> remains complete as the aortic arch. Interruptions here can result in a vascular ring compressing the trachea, like double aortic arch, right aortic arch with left ligamentum arteriosum or pulmonary artery sling (aberrant left pulmonary artery arising from the superior surface of the right pulmonary artery and coursing between the trachea and esophagus).<sup>29</sup>

## **CARDIAC SEPTATION**

Septation of the ventricles begins at about embryonic day 25. The muscular part of inter-ventricular septum grows from the bottom (apex) to the top where the large part is constituted of the perimembranous septum. Naturally defects have results in muscular VSD or perimembranous VSD.

Septation of the atria begins at 30 days of embryonic life. It grows from both sides (septum primum) leaving a patent foramen ovale (PFO) open in the middle. A second septum, septum secundum is

then growing down to the right of the septum primum. The secundum part does not cover the foramen ovale during fetal life, because it is important that the PFO remains open until after birth<sup>28,29</sup>.


Lastly the septation of the out flow vessel is completed between day 35-42. The out flow septation from one into two, is formed as a spiral and if something goes wrong here, the result can be a common atrial trunk (truncus arteriosus), aorta pulmonary window (APW), transposition of the great arteries (the out flow wall is growing straight instead of spiral formed causing parallel outflows), tetralogy of fallot (the wall is shifted rightwards) or hypoplastic left heart syndrome (HLHS) when the wall is shifted leftwards. The conducting system develops from day 35 to birth and the coronary circulation between day 48-51. Innervation of the heart takes place from day 49 to birth. Formation of the AV valves occurs by excavation and cushions in the ventricles and semilunar valves of excavations and growth in the pulmonary artery and aorta. Incomplete formation of the valves can result in Ebstein anomaly, stenosis or atretic valves.

## **FETAL CIRCULATION**

In the fetal circulation, the right and left ventricles exist in a parallel circuit, as opposed to the series circuit of a newborn or adult. In the fetus, the placenta provides for gas and metabolite exchange. The lungs do not provide gas exchange, and vessels in the pulmonary circulation are venous constricted. Three cardiovascular structures unique to the fetus are important for maintaining this parallel circulation: the ductus venosus, foramen ovale, and ductus arteriosus.

Oxygenated blood returning from the placenta flows to the fetus through the umbilical vein with a PO<sub>2</sub> of about 30-35 mm Hg. Approximately 50% of the umbilical venous blood enter the hepatic circulation, whereas the rest bypasses the liver and joins the inferior vena cava via the ductus venosus, where it partially mixed with poorly oxygenated inferior vena cava blood derived from the lower part of the fetal body. This combined lower body plus umbilical venous blood flow (PO<sub>2</sub> of = 26-28 mm Hg) enters the right atrium and is preferentially directed across the foramen ovale to the left ventricle and is ejected into the ascending aorta. Fetal superior vena cava blood, which is considerably less oxygenated (PO<sub>2</sub> of 12-14 mm Hg), enters the right atrium and preferentially traverses the tricuspid valve, rather than the foramen ovale, and flow primarily to the right ventricle.

# FETAL CIRCULATION



From the right ventricle, the blood is ejected into the pulmonary artery. Because the pulmonary arterial circulation is vasoconstricted, only about 10% of right ventricular outflow enters the lungs. The major portion of this blood (which has a PO<sub>2</sub> of = 18-22 mm Hg) bypasses the lungs and flows through the ductus arteriosus into the descending aorta to perfuse the lower part of the fetal body, after which it returns to the placenta via the two umbilical arteries. Thus, the upper part of the fetal body (including the coronary and cerebral arteries and those to the upper extremities) is perfused exclusively from the left ventricle with blood that has a slightly higher PO<sub>2</sub> than the blood perfusing the lower part of the fetal body, which is derived mostly from the right ventricle. Only a small volume of blood from the ascending aorta (10% of fetal cardiac output) flows across the aortic isthmus to the descending aorta.<sup>109</sup>



## **THE TRANSITION FROM FETAL TO NEONATAL CIRCULATION**

With birth, the function of gas exchange is transferred from the placenta to the lungs, and therefore from the systemic circulation to the pulmonary circulation. The venous and arterial circulations are separated, and not only are the fetal shunts unnecessary, but their persistence may lead to circulatory compromise. The transition from the fetal to the neonatal circulation thus includes elimination of the placental circulation, lung expansion, and increase in lung blood flow so that the entire cardiac output can be accommodated, and closure of the foramen ovale, ductus arteriosus, and ductus venosus.

For most congenital structural heart disease, the fetal shunt pathways allow redistribution of ventricular blood flows so that systemic blood flow is adequate and fetal growth and developments are usually normal. Uncomplicated VSDs do not alter the circulation significantly in either the fetus or immediate newborn period, with the important exception of premature infants. With severe left heart obstruction, the burden of systemic and pulmonary blood flow is transferred to the fetal right ventricle, with reversal of blood flow at the foramen ovale, and systemic blood flow almost entirely transmitted via the ductus arteriosus. This "ductal-dependent" systemic circulation is poorly tolerated in the newborn, because normal closure of the ductus arteriosus progressively

decreases systemic blood flow and progresses to circulatory failure and shock. Severe right heart obstruction is also well tolerated in the fetus, because the combined fetal cardiac output can be transferred to the aorta, with the ductus arteriosus supplying predominantly lung blood flow. After birth, such "ductal-dependent" pulmonary blood flow can lead to critically low levels of pulmonary blood flow and severe cyanosis with closure of the ductus arteriosus.

An understanding of fetal hemodynamics and the acute and chronic changes that occur with transition to the newborn circulation are important for the care of normal newborns and are crucial to the recognition, diagnosis, and management of the newborn with significant congenital heart disease.<sup>109</sup>

### **CAUSES OF CONGENITAL HEART DEFECTS<sup>31</sup>**

The etiology is multifactorial including

- Genetic factors (chromosomal disorders, single – gene disorders and polygenic disorders)
- Environmental risk factors (smoking, paints, varnishing, pesticides, solvents and hair dye).
- Teratogenic drugs

Alcohol (septal defects)

Diazepam, Corticosteroids, Hydantoin (pulmonary and aortic stenosis),

Lithium, Trimethadione (transposition of the great arteries,  
Tetralogy of fallot, hypoplastic left heart syndrome),  
Folate antagonists, thalidomide (conotruncal abnormalities),  
Retinoic acid (conotruncal and aortic arch abnormalities)


- Maternal disease increasing the risk are Epilepsy (pulmonary stenosis), poorly controlled Diabetes (tetralogy of Fallot, truncus arteriosus, double outlet right ventricle), poorly controlled Phenylketonuria (Tetralogy of Fallot), Systemic Lupus Erythematosus (AV – block grade III).
- Infections such as Rubella during the first trimester (Patent Ductus Arteriosus and peripheral pulmonary artery stenosis) and other viral infections (Coxsackie and HIV).

## **STRUCTURAL CARDIAC DEFECTS**


They are classified into

- (i) Acyanotic congenital heart defects.
- (ii) Cyanotic congenital heart defects.

## Acyanotic Defects



## Cyanotic Defects



## **CLINICAL PRESENTATIONS OF CONGENITAL HEART DISEASE IN THE NEONATE**

The timing of presentation and accompanying symptomatology depend on

- Nature and severity of the anatomic defect.
- The alterations in cardiovascular physiology secondary to the effects of the transitional circulation. (closure of the ductus arteriosus and the fall in pulmonary vascular resistance).

In the first few weeks of life, the many heterogeneous forms of heart diseases were presented in a limited number of ways. They are

- Heart murmur
- Cyanosis
- Congestive heart failure
- Arrhythmia

### **HEART MURMUR**

Heart murmurs are not uncommonly heard when examining neonates. Estimates of the prevalence of heart murmurs in neonates vary widely from <1% to 50%> depending on the study. Murmurs heard in newborns in the first days of life are often associated with structural heart disease of some type, and therefore may need further

evaluation, particularly if there are any other associated clinical symptoms.

Pathologic murmurs tend to appear at characteristic ages. Semilunar valve stenosis (systolic ejection murmurs) and atrioventricular valvar insufficiency (systolic regurgitant murmurs) tend to be noted very shortly after birth, on the first day of life. In contrast, murmurs due to left to right shunt lesions (systolic regurgitant ventricular septal defect murmur or continuous PDA murmur) may not be heard until the second to fourth week of life, when the pulmonary vascular resistance has decreased and the left-to-right shunt increase. Therefore, the age of the patient when the murmur is first noted and the character of the murmur provide important clues to the nature of the malformation.<sup>107</sup>

## **CYANOSIS**

Cyanosis (bluish tinge of the skin and mucous membranes) is one of the presenting signs of congenital heart disease in the neonate. Cyanosis usually indicates underlying hypoxemia (diminished level of arterial oxygen saturation). Depending on the underlying skin complexion, clinically apparent cyanosis is usually not visible until there >3 g/dl of desaturated hemoglobin in the arterial system. Therefore, the degree of visible cyanosis depends on both the severity of hypoxemia (which determines the percent of oxygen

saturation) as well as the hemoglobin concentration. For example, consider two infants with similar degrees of hypoxemia each having an arterial oxygen saturation of 85%. The polycythemic newborn (hemoglobin of 22g/dL) will have 3.3 g/dL (15% of 22) desaturated hemoglobin and be more easily appreciated to be cyanotic than the anemic infant (hemoglobin of 10 g/dL) who will only have 1.5 g/dL (15% of 10) deasaturated hemoglobin. True central cyanosis should be a generalized finding (i.e., not acrocyanosis, blueness of the hands and feet only, which is a normal finding in a neonate).<sup>107</sup>

### **CONGESTIVE HEART FAILURE(CHF)**

CHF in the neonate is a Clinical diagnosis made on the basis of the existence of certain signs and symptoms rather than on radiographic or laboratory findings (although these may be supportive evidence for the diagnosis). In early stages, the neonate may be tachypneic and tachycardiac, with an increased respiratory effort, rales, hepatomegaly, and delayed capillary refill. In contrast to adults, edema is rarely seen. Diaphoresis, feeding difficulties, and growth failure may be present. Finally, CHF may present acutely with cardiorespiratory collapse, particularly in “left-sided” lesions. Hydrops fetalis is an extreme form of intrauterine CHF.<sup>107</sup>

## **Critical Congenital Heart Disease (CCHD)**

1. All babies with duct dependent circulation are included in this group. But a baby can have a life threatening heart defect and not being defined as duct dependent. “Paediatric cardiologists commonly defines” CCHD as a condition that either is duct dependent or requires surgery or intervention during the first month of life to survive.<sup>32,33</sup>
2. Mellander and Sunnegardh use the definition of critical as “a heart defect that most likely would have caused circulatory collapse or death if surgery or catheter intervention had not been performed before 2 months of age”.<sup>12,34</sup>.
3. **Sendelbach et al.** defined CCHD by listing diagnoses, not severity or time before death or intervention and include tetralogy of Fallot, pulmonary atresia, truncus arteriosus, transposition of the great arteries, total anomalous pulmonary venous return and tricuspid atresia in the cyanotic group and coarctation of the aorta, critical aortic stenosis, interrupted aortic arch and hypoplastic left heart syndrome in the left heart obstructive group<sup>6</sup>.

## **DUCT DEPENDENT LESIONS**

In certain conditions the presence of patent ductus is essential for existence of life. In the absence of blood flow in the ductus the child will



die. This is called an obligatory PDA. The conditions that require a patent ductus are as follows<sup>108</sup>

1. Ductus is the only means of the pulmonary blood flow

- Pulmonary atresia with intact ventricular septum
- Tricuspid atresia with intact septum

2. Ductus is the only means of the systemic blood flow

- Aortic atresia
- Preductal coarctation of aorta
- Hypoplastic left heart syndrome

3. Ductus is the means of bidirectional blood flow

- Transposition of great arteries with intact septum

## **CUSTOMARY PRACTICE**

Timely diagnosis of congenital heart disease (CHD) is challenging but critical. Children with such life threatening defects may not initially have symptoms or the symptoms may be vague, and the condition is not detected in the majority of cases<sup>23, 36, 37.</sup>

Strategies that have been suggested to improve early detection of CHD include prenatal ultrasound screening, prolonged hospital stay after delivery, one or more post discharge examinations during the first or the following two weeks of life, and training clinicians to detect “silent” CHD. However, all these strategies are cumbersome and costly and their

value is doubtful. Despite the apparent need, until recently, there were no other means for early detection of CHD<sup>14,39,40</sup>.

Since the late 1980s, prenatal ultrasound has been used to screen for congenital anomalies. An anatomic ultrasound is typically performed at 18 to 20 weeks gestation. During this process many, but not all, cases of CHD can be identified by a methodical scan.<sup>41</sup>

Prenatal ultrasound, performed by those with specific training in congenital heart disease, can identify a variety of CHD lesions. However, numerous studies have reported that even when fetal ultrasound is routinely performed during pregnancy, fewer than 50% of cases of CHD are identified<sup>42-47</sup>.

There are several factors that might account for the relatively low prenatal CHD detection rate. The quality of anatomic ultrasounds varies considerably. A number of medical professionals, including radiologists, perinatologists, and general obstetricians with varying degrees of training, as well as technicians, perform these ultrasounds. In addition to concerns about the quality, there may be limited access to prenatal ultrasound. The availability of anatomic ultrasound is likely to be particularly limited in certain low socioeconomic status groups. Therefore, although prenatal ultrasound plays an important part in the timely identification of CHD,

population based data demonstrate that this methodology by itself is insufficient to identify a high proportion of cases.<sup>48-52</sup>

Screening for congenital heart disease by primary care providers is currently accomplished by physical examination and on subsequent nursery visits. Supplemental tests, including electrocardiograms, pulse oximetry, and chest radiographs, are often obtained in suspicious cases.<sup>26</sup>

Skilled physical examination, a sensitive and specific screening tool in older children, does not always distinguish between neonates with and without congenital heart disease.<sup>54,55</sup> Hypoxemia is difficult to detect in newborns, and the transitional circulation masks important clinical findings such as absent femoral pulse while the ductus arteriosus remains patent. Perhaps most importantly, physical examination skills are on the decline in current trainees.<sup>56</sup>

Heart murmurs have a prevalence of between 0.6% and 4.2% in newborns and are mistakenly considered a hallmark of heart disease.<sup>24,57</sup> They often do not accompany critical heart defects, particularly those with valve Atresia and transposition. Flow murmurs of the transitional circulation, transient tricuspid regurgitation, and small ventricular septal defects are common and of no clinical importance in newborns. Conversely, murmurs of many important complex heart defects, such as

tricuspid atresia with ventricular septal defect, double – outlet right ventricle, and total anomalous pulmonary venous return, emerge only after the decline in pulmonary resistance and after neonatal discharge and are often heard but not considered pathological. Practicing pediatricians currently have limited experience in discriminating innocent from pathological murmurs. In a contemporary series in which echocardiography was performed to evaluate for possible heart disease based on suspicious physical examination, fewer than 15% of subjects were found to have significant congenital heart disease<sup>53</sup>.

Clinical experience and epidemiological observations suggest that although physical examination, electrocardiogram, and chest radiograph are useful identifying many cases of serious congenital heart disease postnatally, they do not have sufficient sensitivity and specificity to detect all cases. Echocardiography, although an essential diagnostic tool, has serious limitations as a universal screening tool, particularly its cost.<sup>55</sup> When used positive results (usually related to the transitional circulation) of either false or clinically benign diagnoses (eg, small muscular ventricular septal defects). In addition, there may be an inadequate supply of trained personnel who could perform this screening with a reasonable degree of accuracy. Therefore, there is considerable interest in improving the detection of CHD with novel diagnostic techniques.<sup>105</sup>

## **PULSE OXIMETRY AND DETECTION OF CHD**

A common feature of many forms of congenital heart disease is hypoxemia. Hypoxemia results from the mixing of systemic and venous circulations or parallel circulations as one might see in dextro-transposition of the great arteries. Hypoxemia may result in obvious cyanosis. However, generally, 4 to 5 g of deoxygenated hemoglobin is needed to produce visible central cyanosis, independent of hemoglobin concentration<sup>58</sup>. For the typical newborn with a hemoglobin concentration of 20 g / dL, cyanosis will only be visible when arterial oxygen saturation is <80%; if the infant only has a hemoglobin concentration of 10 g / dL. The saturation must be <60% before cyanosis is apparent. Importantly, those children with mild hypoxemia, with arterial oxygen saturation of 80% to 95%, will not have visible cyanosis. Moreover, the identification of cyanosis is particularly problematic in black and Hispanic neonates because of skin pigmentation<sup>58</sup>.

The majority of CHD lesions present with some degree of hypoxemia in the newborn period. The below table demonstrates the frequency of the most common forms of CCHD based on data from the Metropolitan Atlanta Congenital Birth Defects Surveillance Program and the likelihood of having some degree of hypoxemia in the newborn period. To improve timely detection of CHD, a number of investigators

have proposed that pulse oximetry be considered as a complementary modality to the newborn physical examination<sup>11,73</sup>.

| LESION                                | PREVALENCE / 10000 LIVE BIRTH | HYPOXEMIA |
|---------------------------------------|-------------------------------|-----------|
| <b>OUTFLOW TRACT DEFECTS</b>          |                               |           |
| Tetralogy of fallot                   | 6.1                           | MOST      |
| D-transposition of the great arteries | 4.0                           | ALL       |
| Double – outlet right ventricle       | 1.7                           | SOME      |
| Truncus arteriosus                    | 1.0                           | ALL       |
| TAPVC                                 | 1.2                           | ALL       |
| Ebstein anomaly                       | 0.6                           | SOME      |
| <b>RIGHT OBSTRUCTIVE DEFECTS</b>      |                               |           |
| Tricuspid atresia                     | 0.5                           | ALL       |
| Pulmonary atresia with intact septum  | 0.8                           | ALL       |
| Pulmonary stenosis, atresia           | 6.3                           | SOME      |
| <b>LEFT OBSTRUCTIVE DEFECTS</b>       |                               |           |
| Hypoplastic left heart                | 3.3                           | ALL       |
| Coarctation of the aorta              | 4.7                           | SOME      |
| Aortic arch atresia or hypoplasia     | 1.0                           | SOME      |
| Critical aortic valve stenosis        | 1.6                           | UNCOMMON  |
| <b>OTHER MAJOR HEART DEFECTS</b>      | 12.4                          | SOME      |

Pulse oximetry is used routinely in the assessment of young children in neonatal intensive care units and emergency departments and has been proposed as an adjunct to the assessment of the new born in the delivery room<sup>62</sup>(Neonatal Resuscitation Protocol 2010 guidelines). As such, some have proposed that pulse oximetry be considered as a vital sign equivalent in importance to pulse, respirations, and blood pressure<sup>63</sup>.

## **PULSE OXIMETRY SCREENING**

Every baby is cyanotic until birth. The first breaths and increasing pulmonary circulation induce a rapid rise in pulse oximetry oxygen saturation (Spo<sub>2</sub>).

## **PULSE OXIMETRY IN THE NORMAL NEW BORN**

The mean preductal (right hand) and postductal (foot) SpO<sub>2</sub> of healthy newborns at the age of 2 min has been shown to be 73% (range 44–95%) and 67% (34–93%), respectively. In that study of 50 newborns, these values increased at 10 min to 92% (65–99%) and 89% (62–99%), respectively, and in every newborn both measurements reached 95% within 1hr. The reduction in the difference between preductal and postductal measurements reflects the diminishing ductal right to left shunt. However, a slower disappearance of the shunt has been seen in 4–5% among larger populations. Thus, use of SpO<sub>2</sub> for screening is not practical before the age of 1–2 h. Thereafter, the normal baseline SpO<sub>2</sub> is quite stable at about 98%, except for short periods when it is lower, in particular during feeding and apnoeic spells<sup>10, 64-66</sup>.

O'Brien and colleagues have defined reference data for oxygen saturation in healthy full term infants during their first 24 hours of life. The median value at 20 to 24 hours of life (97.8%) is similar to the results for healthy full-term infants between 2 and 7 days of age (97.6%). Other investigators have reported similar results<sup>66-69</sup>.

## **PULSE OXIMETRY IN CONGENITAL HEART DISEASE**

Byrne et al found that cyanotic CHD with obligatory or mixing cyanosis was associated with either a generally low level of SpO<sub>2</sub> <88%.<sup>70</sup> However, a pure left to right shunt does not affect systemic oxygenation and is not detectable by pulse oximetry. These phenomena form the basis of pulse oximetry screening for CHD.

## **AGE AT PULSE OXIMETRY SCREENING**

Because newborns with critical congenital heart disease (CCHD) may have clinical deterioration in the first 48 hours of life, one would ideally use oximetry screening soon after delivery. However, arterial oxygen saturation varies considerably in the first 24 hours, with many healthy newborns having arterial saturations of less than 95%. As such, oximetry screening before 24 hours of life can result in a significant number of false-positive results. A study from the United Kingdom reported that the false-positive rate was as high as 5% when oximetry screening was performed in the first 24 hours compared with 1% at the time of hospital discharge<sup>71</sup>. Therefore, to achieve an acceptable specificity, testing 24 hours after birth would appear to be the most reasonable strategy.



## **CUT-OFF SATURATION**

The establishment of a cutoff threshold for an abnormal SpO<sub>2</sub> is important. Other factors being constant, a higher threshold will increase sensitivity and at the same time decrease specificity. Setting the SpO<sub>2</sub> cutoff value closer to the normal level will decrease the number of false-negative screening results at the cost of increasing the number of false-positive screening results. Conversely, a lower SpO<sub>2</sub> threshold will lower sensitivity and raise specificity. Although a number of SpO<sub>2</sub> thresholds have been proposed, many investigators believe that an SpO<sub>2</sub> of <95% is appropriate. One study suggested that SpO<sub>2</sub> <92% be considered a positive sign of hypoxemia however, others have argued that a low threshold is likely to result in a number of infants with critical congenital heart disease (CCHD) being misclassified as normal without markedly improving specificity<sup>72</sup>.

## **PROBE SITE**

Newborns who have obligatory or mixing cyanotic CHD have reduced SpO<sub>2</sub> both preductally and postductally. Defects with post ductal dependent systemic circulation exhibit higher preductal than post ductal SpO<sub>2</sub> due to right to left shunting of unoxygenated blood to lower body<sup>73</sup>. Pulse oximetry screening is thus most effective with postductal probe placement.

## **SIGNAL QUALITY AND NEWBORN BEHAVIOUR**

Technical errors are minimized by accepting only high quality pulse oximetry signals confirmed by a good pulse signal displayed simultaneously.<sup>75,76</sup> Measurements should not be made when the infant is moving, crying, eating or has an apnoeic spell.<sup>66,76</sup> The heart rate displayed by the oximeter should be within the range expected for a calm, regularly breathing newborn (about 90–160/min). The highest stable SpO<sub>2</sub> value, maintained longer than the averaging time of the pulse oximetry, is recorded.<sup>37,74,75</sup>

## **LIMITATIONS OF PULSE OXYMETRY SCREENING**

There are technical limitations to oximetry measurement in the newborn. As noted above, the mean SpO<sub>2</sub> in the newborn at 24 hours of age is 97% to 98%. However, when continuous pulse oximetry is used, multiple investigators have demonstrated periodic and or sustained desaturation below 95% during sleep, feeding, and crying.<sup>64,66,69,77</sup> Sustained rather than variable hypoxemia is consistent with the diagnosis of cyanotic congenital heart disease. Low oximetry readings in the setting of normal arterial oxygen saturation have been reported by multiple investigators.<sup>78,79</sup> In fact, falsely low oximetry readings in the newborn population are known to be associated with low peripheral perfusion and

motion artifact,<sup>80,81</sup> probe placement site and partial probe detachment<sup>82</sup>, and hyperbilirubinemia or dyshemoglobinemias.

There has also been concern that pulse oximeters may not be as accurate in darkly pigmented adults and children. At low SpO<sub>2</sub> levels 70%, commercially available oximeters appear to overestimate arterial saturation by 3% in darkly pigmented subjects<sup>85</sup>. However, when SpO<sub>2</sub> is 90%, measurement bias related to skin pigmentation appears negligible (0.2%). Lastly, the quality of oximetry measurements may be lower when performed in a screening setting.<sup>9</sup>

## **PULSE OXIMETRY**

The first commercially available pulse oximeter was developed by Takuo Aoyagi and was marketed by Nihon Koden in 1974.

Pulse oximetry is a non-invasive way of measuring the oxygen saturation in arterial blood SpO<sub>2</sub>. A pulse oximeter is based on spectral analysis and combines two technologies, spectrophotometry and optical plethysmography.<sup>87</sup>

## **SPECTROPHOTOMETRY**

A spectrophotometer measures light intensity as a function of the colour or more specifically the wavelength of light. There are two classes of spectrophotometers, single beam and double beam. Single beam spectrophotometer measures the absolute light intensity, whereas double

beam spectrophotometer measures the ratio of the light intensity from two different light paths. The pulse oximeters use double beam for measuring the hemoglobin oxygen saturation.

## **OPTICAL PLETHYSMOGRAPHY**

A plethysmograph is a pulse-volume recorder, a way of measure the pulsatile changes from the arterial blood at the sensor site.


## **PRINCIPLES OF PULSE OXIMETRY TECHNOLOGY**

The principle of pulse oximetry is based on the red and infrared light absorption characteristics of oxygenated and deoxygenated hemoglobin. Oxygenated hemoglobin absorbs more infrared light and allows more red lights to pass through. Deoxygenated (or reduced) hemoglobin absorbs more red light and allows more infrared light to pass through. Red light is in the 600-750 nm wavelength light band. Infrared light is in the 850-1000 nm wavelength light band.


Pulse oximetry uses a light emitter with red and infrared LEDs that shines through a reasonably translucent site with good blood flow. Typical adult and pediatric sites are the finger, toe, pinna (top) or lobe of the ear. Infant sites are the foot or palm of the hand and the big toe or thumb. Opposite the emitter is a photo detector that receives the light that passes through the measuring site.

The principle of Beer Lambert law is used to measure the relative concentrations of reduced hemoglobin (RHb) and oxygenated hemoglobin ( $O_2$  Hb) in pulse oximeters. The ratio of light absorbed at the red light to that of infrared light  $A_{660nm}$  (RHb) /  $A_{940 nm}$  ( $O_2$  Hb) correlates with oxygen saturation, since the concentration of a given solute in a solvent is measured by the amount of light that is absorbed by the solute at a specific wavelength.<sup>87</sup> After the transmitted red (R) and infrared (IR) signals pass through the measuring site and are received at the photodetector, the R/IR ratio is calculated. The R/IR is compared to “look-up” tables (made up of empirical formulas) that convert the ratio to a SpO<sub>2</sub> value. Most manufacturers have their own look-up tables based on calibration curves derived from healthy subjects at various SpO<sub>2</sub> levels.<sup>88</sup>


A pulse oximeter can be calibrated in two ways, either displaying functional saturation or fractional saturation.<sup>69,89</sup> Functional saturation is the quantity of Oxyhaemoglobin ( $HbO_2$ ) expressed as a percent of haemoglobin that can transport oxygen (since Methb and COHB cannot transport oxygen, they are not included). The functional SpO<sub>2</sub> value is obtained by multiplying the fractional saturation by 1.02. Fractional saturation is the  $HbO_2$  expressed as a percent of all the hemoglobin measured, including carboxyhaemoglobin and



Difference in wavelength of red and infrared light



Light emitter with red and infrared LED being received by photodetector which passes through the measuring site.



The different tissues affecting light absorption

methaemoglobin.<sup>87,90</sup> That means that a pulse oximeter calibrated for fractional saturation displays about 2% lower values than an oximeter calibrated for functional saturation.<sup>69,91</sup> The calibrations are performed by the manufacturer and thus cannot be changed by the user.

$$\text{Functional SpO}_2 = \frac{\text{O}_2\text{Hb}}{\text{O}_2\text{Hb} + \text{RHb}} \times 100$$

$$\text{Fractional SpO}_2 = \frac{\text{O}_2\text{Hb}}{\text{O}_2\text{Hb} + \text{RHb} + \text{MetHb} + \text{COHb}} \times 100$$

The major change that occurred from the oximeters of the 70s to the oximeters of today was the inclusion of arterial pulsation to differentiate the light absorption in the measuring site due to skin, bone, pigmentation and venous blood, from that of arterial blood. The former absorbs a constant amount of light over the time. The arteriolar bed pulsates and absorbs variable amounts of light during systole (peak) and diastole (trough), as blood volume increases and decreases. The ratio of light absorbed at the peak and trough is translated into an oxygen saturation measurement. Since peaks occur with each heartbeat or pulse, the term pulse oximetry was coined.

## **LIMITATIONS WITH CONVENTIONAL TECHNOLOGY**

### **PULSE OXIMETRY<sup>92-103</sup>**

- Motion artifact (when the patient is moving, the venous blood is also moving and the pulse oximeter adds the moving venous blood to the AC component, thus the displayed SpO<sub>2</sub> is underestimated).
- Light interference (phototherapy and bright light can affect SpO<sub>2</sub> accuracy).
- Skin pigmentation (overestimations of SpO<sub>2</sub> in dark pigmented skin, as skin darkens, the oximeter performance deteriorates. This could be a result of empirical calibration data derived from predominantly white volunteers).
- Low peripheral perfusion states
- Dyshaemoglobinemia (carboxyhemoglobin and methemoglobin are unable to carry oxygen. SpO<sub>2</sub> readings may appear normal even in the hypoxic patient.)
- Low oxygen saturation
- Nail polish
- Irregular heart rhythm
- Temperature (low peripheral temperature and vasoconstriction contributes to inaccuracy).



Still, conventional pulse oximetry accuracy suffered greatly during motion and low perfusion and made it difficult to depend on when making medical decisions. The advent of "**NEXT GENERATION**" pulse oximetry technology has demonstrated significant improvement in the ability to read through motion and low perfusion<sup>92-103</sup>.

## **AIM AND OBJECTIVES**

- To detect the usefulness of pulse oximetry screening in early detection of congenital heart disease (CHD).
- To evaluate combined pulse oximetry and clinical examination as a screening method for congenital heart disease (CHD) in asymptomatic newborns.

## **MATERIALS AND METHODS**

### **STUDY DESIGN**

Prospective study

### **STUDY PLACE**

Post natal ward, Government Rajaji Hospital, Madurai.

### **STUDY PERIOD**

September 2010 to August 2011

### **STUDY POPULATION**

New born babies present in postnatal ward of Government Rajaji Hospital, Madurai.

### **INCLUSION CRITERIA**

ASYMPTOMATIC TERM NEW BORN babies present in post natal ward.

### **EXCLUSION CRITERIA**

Sick babies admitted to NICU at birth, Preterm babies, newborn babies with prenatal diagnosis of CHD, babies with external congenital anomaly were excluded from the study.

## **METHODOLOGY**

This study was a hospital based prospective study. In this study we screened asymptomatic term new born babies in the post natal ward for congenital heart disease using pulse oximetry and cardiac clinical examination between September 2010 and August 2011.

Sick babies admitted to NICU at birth, preterm babies, newborn babies with prenatal diagnosis of CHD, babies with external congenital anomaly were excluded from this study.

Asymptomatic term new born babies were screened by pulse oximetry using **NELLCOR OXIMAX N- 95 HAND HELD NEW GENERATION PULSE OXIMETER**. Pulse oximetry readings were taken in a quiet or sleeping newborn from right foot. The probe was cleansed with alcohol swab before each use.

The readings were recorded after stabilization for one minute, according to the manufacturer instructions. The functional oxygen saturation of  $\geq 95\%$  was accepted as normal. If the new born baby had oxygen saturation below 90%, echocardiography was performed. In the case of a new born with oxygen saturation between 90%-94%, a second measurement was performed six hours later. If the oxygen saturation remained below 95%, echocardiography was performed.

**NELLCOR OXIMAX N – 95 HAND HELD  
NEW GENERATION PULSE OXIMETER**




**PULSE OXIMETRY SCREENING**



Cardiac clinical examination screening was also performed for all babies simultaneously with pulse oximetry screening. We looked for central cyanosis and cardiac murmur. Echocardiography was performed for babies having cardiac murmur or central cyanosis. The cardiac clinical examination and pulse oximetry screening were carried out between 24 to 48 hours of age.

New born babies who underwent echocardiography were categorized as having either a normal heart or a structurally malformed heart.

# STUDY PROTOCOL



## **OBSERVATION AND RESULTS**

A total of 2437 asymptomatic term newborn babies entered the study and they were screened by pulse oximetry and clinical examination. Male babies were 1269(52%). Female babies were 1168(48%). Screening was performed at a median age of 36 hours. Birth weight ranged from 2kg to 3.8 kg. Average birth weight was 2.6kg. 24.5% of babies were born to consanguineous parents and 75.5% of babies were born to nonconsanguineous parents. 50% of babies were of first order. 51.4% of babies were delivered by labour naturale.


**Table - 1**

### **SEX DISTRIBUTION OF SCREENED BABIES**

| <b>SEX</b> | <b>NUMBER</b> | <b>PERCENTAGE</b> |
|------------|---------------|-------------------|
| MALE       | 1269          | 52%               |
| FEMALE     | 1168          | 48%               |
| TOTAL      | 2437          | 100%              |



SEX DISTRIBUTION OF SCREENED BABIES





■ Male ■ Female

**Table - 2**

**MODE OF DELIVERY OF SCREENED BABIES**

| <b>MODE OF DELIVERY</b> | <b>NUMBER</b> | <b>PERCENTAGE</b> |
|-------------------------|---------------|-------------------|
| NATURAL LABOUR          | 1254          | 51.4%             |
| LSCS                    | 970           | 39.8%             |
| OUTLET FORCEPS          | 165           | 6.8%              |
| BREECH                  | 48            | 2.0%              |
| TOTAL                   | 2437          | 100%              |

### MODE OF DELIVERY



**Table - 3**

**PULSE OXIMETRY SCREENING**

|   |            |
|---|------------|
| Total number of babies screened   | 2437       |
| Total number of babies with negative screening (Oxygen saturation $\geq 95\%$ )                                     | 2413 (99%) |
| Total number of babies with positive screening (Oxygen saturation $< 95\%$ )  | 24(1%)     |
| Total number of CHD confirmed by Echocardiography in babies with positive pulse oximetry screening                  | 17(70.8%)  |
| Total number of babies with positive pulse oximetry screening but having NORMAL HEART confirmed by Echocardiography | 7(29.2%)   |

2,231(91.5%) new borns had oxygen saturation values greater or equal to 95%, while 206(8.5%) newborns had oxygen saturation less than 95%. Out of 206 babies 3 babies had oxygen saturation less than 90%, 203 babies had oxygen saturation between 90%-94%. Pulse oximetry measurements were repeated after 6 hours for the 203 babies. The results showed that 21 babies had **persistent** low oxygen saturation between 90 to 94% and other 182 babies had oxygen saturation greater or equal to 95%. A total of 24 babies (1%) required echocardiography because of low oxygen saturation values (3 babies- $< 90\%$ , 21 babies 90-94%).


3 echocardiograms were done based on low pulse oximetry value < 90%. One had saturation of 88% and was diagnosed with TRICUSPID ATRESIA. Another baby with saturation of 85% was diagnosed as d-TGA. The third baby had PULMONARY ATRESIA with a saturation of 83%.

21 Echocardiograms were done based on low pulse oximetry values between 90-94%. Among the 21 babies, one had a saturation of 91% and was diagnosed with TOF. Another baby with a saturation of 93% was diagnosed as ASD (OP) with AV canal defect. All other 19 babies had saturation of 94% and echocardiography results showed 7 normal hearts, 8 small PDA and 4 small ASD (OS).

**Table - 4**  
**OXYGEN SATURATION OF BABIES WITH NEGATIVE PULSE**  
**OXIMETRY SCREENING (SpO<sub>2</sub> ≥ 95%)**

| <b>OXYGEN SATURATION (%)</b> | <b>NUMBER OF BABIES</b> | <b>PERCENTAGE (%)</b> |
|------------------------------|-------------------------|-----------------------|
| 95                           | 293                     | 12.1                  |
| 96                           | 490                     | 20.3                  |
| 97                           | 587                     | 24.3                  |
| 98                           | 731                     | 30.3                  |
| 99                           | 193                     | 8.0                   |
| 100                          | 119                     | 5.0                   |
| <b>TOTAL</b>                 | <b>2413</b>             | <b>100</b>            |

OXYGEN SATURATION OF BABIES WITH NEGATIVE PULSE OXIMETRY SCREENING  
(SpO<sub>2</sub> > 95%)



**Table - 5**

**OXYGEN SATURATION OF BABIES WITH POSITIVE PULSE  
OXIMETRY SCREENING (SpO<sub>2</sub> <95%)**



| <b>Oxygen Saturation</b> | <b>No.of Babies</b> |
|--------------------------|---------------------|
| <90%                     | 3                   |
| 90%-94%                  | 21                  |
| Total                    | 24                  |

**Table - 6**

**ECHOCARDIOGRAPHY RESULT OF BABIES WITH OXYGEN  
SATURATION <90%**

| <b>ECHOCARDIOGRAPHY RESULT</b>                      | <b>NUMBER</b> | <b>Oxygen Saturation</b> |
|---|---------------|--------------------------|
| Tricuspid atresia with ASD (os),PDA, sub aortic VSD | 1             | 88 %                     |
| d-TGA, ASD, PDA                                     | 1             | 85%                      |
| Pulmonary atresia with VSD, PDA                     | 1             | 83%                      |
| TOTAL   | 3             |                          |

OXYGEN SATURATION OF BABIES WITH POSITIVE PULSE OXIMETRY SCREEING  
(SpO2 < 95%)





**Table - 7**

**ECHOCARDIOGRAPHY RESULT OF BABIES WITH OXYGEN**

**SATURATION 90%-94%**

| <b>ECHOCARDIOGRAPHY RESULT</b>     | <b>NUMBER</b> |
|------------------------------------|---------------|
| NORMAL HEART                       | 7             |
| SMALL PDA                          | 8             |
| SMALL ASD(OS)                      | 4             |
| LARGE ASD(OP) with AV canal defect | 1             |
| TOF                                | 1             |
| <b>TOTAL</b>                       | <b>21</b>     |


**Table - 8**

**ECHOCARDIOGRAPHY RESULTS OF BABIES WITH**


**POSITIVE PULSE OXIMETRY SCREENING**

| <b>ECHOCARDIOGRAPHY<br/>RESULT</b> | <b>NUMBER</b> | <b>PERCENTAGE</b> |
|------------------------------------|---------------|-------------------|
| CONGENITAL HEART DISEASE           | 17            | 71                |
| NORMAL HEART                       | 7             | 29                |
| <b>TOTAL</b>                       | <b>24</b>     | <b>100</b>        |

ECHOCARDIOGRAPHY RESULT OF BABIES WITH POSITIVE PULSE  
OXIMETRY SCREENING



**PULSE OXIMETRY SCREENING**



**Table - 9**

**CARDIAC CLINICAL EXAMINATION**

|   |               |
|---|---------------|
| Total number of babies screened   | 2437          |
| Total number of babies with negative screening  | 2401 (98.5% ) |
| Total number of babies with positive screening  | 36(1.4%)      |
| Total number of CHD confirmed by Echo Cardiography in babies with positive clinical examination screening                 | 25(69%)       |
| Total number of babies with positive clinical examination screening but having NORMAL HEART confirmed by Echocardiography | 11(31%)       |

Cardiac clinical examination screening was performed simultaneously with pulse oximetry screening. Babies were looked for murmur and cyanosis. 36 babies had murmur and were considered screening positive. None of the baby had central cyanosis.


36 echocardiograms were done based on presence of murmur. Among the 36 babies, echocardiography showed 10 cases of VSD, 2 cases of large ASD(OS),1 case of ASD(OP) with AV canal defect, 3 cases of small ASD, 7 cases of small PDA, 1 case of TOF, and 1 case of isolated dextrocardia. 11 of them showed normal heart. Among these TOF,ASD(OP) with AV canal defect,3 cases of small PDA also had low oxygen saturation in addition to murmur.

**Table - 10**

**ECHOCARDIOGRAPHY RESULT OF BABIES WITH POSITIVE  
CLINICAL EXAMINATION**

| <b>ECHOCARDIOGRAPHY RESULT</b> | <b>NUMBER</b> |
|--------------------------------|---------------|
| NORMAL HEART                   | 11            |
| VSD                            | 10            |
| LARGE ASD(OS)                  | 2             |
| ASD(OP) with AV canal defect   | 1             |
| SMALL ASD(OS)                  | 3             |
| SMALL PDA                      | 7             |
| TOF                            | 1             |
| DEXTROCARDIA                   | 1             |
| <b>TOTAL</b>                   | <b>36</b>     |

### ECHOCARDIOGRAPHY RESULT OF BABIES WITH POSITIVE CLINICAL EXAMINATION SCREENING




## SUMMARY

In our study 2437 babies were screened by pulse oximetry and clinical examination. 31 babies were positive only for clinical examination screening. Out of 31, 20 babies had congenital heart disease. 19 babies were positive only for pulse oximetry screening. Out of 19, 12 babies had congenital heart disease including 3 life threatening cyanotic congenital heart disease. 5 babies were positive for both screening tests and all 5 had congenital heart disease. In total, 55 babies were screening positive of which 37 babies had congenital heart disease. Our study showed that combined screening method identified more number of cases with congenital heart diseases than any single method of screening. It was found to be statistically significant. (P value-0.0235)

**Table - 11**


| SCREENING METHOD                                  | NUMBER OF BABIES | CHD CONFIRMED BY ECHO | NORMAL HEART CONFIRMED BY ECHO |
|---|------------------|-----------------------|--------------------------------|
| Positive only for cardiac clinical examination(A) | 31               | 20                    | 11                             |
| Positive only for pulse oximeter(B)               | 19               | 12                    | 7                              |
| Positive for both screening test(C)               | 5                | 5                     | 0                              |
| TOTAL NO.OF SCREENING POSITIVE BABIES(A+B+C)      | 55               | 37                    | 18                             |

SUMMARY OF SCREENING POSITIVE BABIES AND THEIR ECHOCARDIOGRAPHY RESULTS





## SCREENING CHARACTERISTICS OF CHD



## **DISCUSSION**

Some babies born with a cardiac defect may appear healthy soon after birth and may be sent home before their cardiac defect is detected. These babies are at risk of developing serious complication within the first few days or weeks of life and may have significant morbidity and mortality. Routine pulse oximetry screening may help in early identification of these babies before they land up in complications.

### **EFFECTIVENESS OF PULSE OXIMETRY SCREENING**

In this study abnormal pulse oximetry was found in 24 babies of which 17 had CHD on echocardiography. 5 babies had major CHD [ 1- Transposition of the Great Arteries(d-TGA), 1- Pulmonary Atresia (PA), 1- Tricuspid Atresia (TA), 1- Tetralogy of Fallot (TOF), 1- ASD(OP) with AV canal defect], 12 babies had minor CHD [4-small ASD, 8-small PDA]. Out of 17 CHD babies, 5 babies had murmur [1-TOF, 1-ASD(OP) with AV canal defect, 3-small PDA] and 12 babies had no murmur.

This study showed that pulse oximetry can detect CHD in asymptomatic new born babies which have been missed by routine clinical examination. Notably pulse oximetry identified cases of life threatening complex cyanotic CHD such as Transposition of great arteries (TGA), Tricuspid Atresia (TA), Pulmonary Atresia (PA), none of which had been detected clinically.

Pure left-to-right shunts such as ventricular septal defect, atrial septal defect, or patent ductus arteriosus should not be detected by pulse oximetry, but some of these defects (5-17%) proved to be screen positive.<sup>10,37,75,104</sup> This happened probably due to bidirectional shunting during early postnatal pulmonary hypertension.

### **TIME OF PULSE OXIMETRY SCREENING**

If pulse oxymetry screening is performed after a few days of life, there will be a reduced incidence of false positives, because of the physiologic decrease in the pulmonary vascular resistance, but a newborn with a ductal-dependant CHD could deteriorate rapidly if the ductus arteriosus had already closed. Measurements performed shortly after birth may lead to an increased number of false positives.<sup>10,104,102</sup>

In this study the babies were screened between 24-48 hours of age in the view of early detection of CHD and to decrease the number of false positive results. The false positive rate of our study is 0.28% which is slightly higher than other studies. This higher false positive rate is due to early screening of healthy babies with delayed transitional circulation.

### **SATURATION CUT-OFF**

Our decision to use a 95% cut-off was based on published normal pulse oximetry values in healthy newborns<sup>66,69</sup> and saturation differences observed in infants with left obstructive heart disease and obligate right to

left shunt across the ductus arteriosus.<sup>60</sup> Pulse oximetry is known to overestimate arterial oxygen saturation at low saturations and underestimate it at high saturations.<sup>84,65,60</sup> The sensitivity and specificity remained quite stable using a cut-off ranging from 92% to 95%, whereas a cut-off below 92% led to a rapid decrease of sensitivity.

## **COMPARISON OF OUR STUDY WITH OTHER PULSE OXIMETRY STUDIES**

Comparison with literature is difficult because the study designs, methods, target CHD, technical details and way of expressing the results are different.

A case-control study, (**Hoke et al; 2002**) included 2,972 newborns admitted to well baby nurseries and 32 newborns with CHD. An oxygen saturation < 92% in the leg or a saturation 7% lower in the leg than in the arm was defined as abnormal. Of the well babies, 57 had an abnormal pulse oximetry reading; of these, four babies were found to have congenital heart defects, including one case of coarctation of the aorta. A fifth baby was found to have pulmonary hypertension. Of the 32 newborns with congenital heart disease, 11/13 (85%) with left-heart obstructive disease had abnormal oxygen saturation as did 15/19 (79%) of babies with other congenital heart defects<sup>73</sup>.

**Reich et al; 2003**, Babies were assessed with a single pulse oximetry reading. Of 2,335 eligible newborns, those with an oxygen saturation  $\leq 94\%$  that persisted with a second reading were further assessed by echocardiogram. An echocardiogram was performed in 88 infants, which was abnormal in 43 babies, and 13 required management. In this study, pulse oximetry was nearly 100% specific for detecting cyanotic congenital heart disease; as a result, there was no increase in the number of echocardiograms generated<sup>26</sup>.

**Koppel et al; 2003** assessed the sensitivity, specificity, predictive value and accuracy of pulse oximetry screening of 11,281 asymptomatic newborns in two hospitals. Diagnostic echocardiogram was performed in infants with oxygen saturation  $\leq 95\%$  within the first 24 hours of life. Three babies with CHD were identified (but none had a critical left-heart obstructive lesion). Two patients with negative screens were later readmitted; one with aortic coarctation and one with hypoplastic left pulmonary artery with aorto-pulmonary collaterals. No unnecessary echocardiograms were generated by the study. The sensitivity of the screening test was calculated to be 60%, with a specificity of 99.95%, a positive predictive value of 75% and a negative predictive value of 99.98%.<sup>11</sup> Our study also did not identify critical left heart obstructive

lesion like Hypoplastic left heart syndrome, coarctation of aorta, critical aortic stenosis.

**Arlettaz et al; 2006** evaluated the effectiveness of pulse oximetry screening to detect structural CHD on the first day of life in all babies (n=3,663) born during a one-year period who were > 35 weeks gestation and had no respiratory distress. Also evaluated was whether pulse oximetry combined with clinical examination is superior to clinical exam alone to diagnose CHD. Oxygen saturation readings from one foot were considered normal with oxygen saturations > 95%. Twenty-four infants had repeated oxygen saturations < 95% and had an echocardiogram. Of these, 17 had CHD and five had pulmonary hypertension. One child had a myocardial tumour and one infant had a normal heart. No false negative cases were reported <sup>75</sup>. This study showed high detection rate of CHD by pulse oximetry. This may be due to inclusion of babies with CHD diagnosed prenatally.

**Bakr et al: 2005** evaluated combined pulse oximetry and clinical examination as a screening method for CHD in all asymptomatic infants (excluding those admitted to the neonatal unit) born during a six-month period. Of 5,211 infants, five babies were identified with an oxygen saturation <94%, which was considered abnormal. One infant had total anomalous pulmonary venous return, one had pulmonary atresia, one had

a large ventricular septal defect and another child had a truncus arteriosus. The fifth child had a normal heart. Three babies were later diagnosed with CHD that was not detected by pulse oximetry screening when being investigated for failure to thrive and respiratory symptoms. The sensitivity of the combined method of screening was 77%, whereas it was 30.8% for oximetry alone and 46% for clinical exam alone, Specificity was approximately 100% for all methods. The positive predictive value was 80% for pulse oximetry alone<sup>37</sup>.

**Table - 12****DETECTION OF CRITICAL CONGENITAL HEART DISEASE  
(CCHD) LESIONS FROM PULSE OXIMETRY SCREENING STUDIES**

| <b>CHD</b>                           | <b>Hoke<sup>73</sup></b> | <b>Richmond<sup>10</sup></b> | <b>Koppel<sup>11</sup></b> | <b>Reich<sup>26</sup></b> | <b>Bakr<sup>37</sup></b> | <b>Rosati<sup>74</sup></b> | <b>Arlettaz<sup>75</sup></b> | <b>Kawalec<sup>53</sup></b> | <b>Our<br/>study</b> |
|--------------------------------------|--------------------------|------------------------------|----------------------------|---------------------------|--------------------------|----------------------------|------------------------------|-----------------------------|----------------------|
| <b>NO OF<br/>BABIES<br/>SCREENED</b> | 2876                     | 5626                         | 11281                      | 2114                      | 5211                     | 5292                       | 3262                         | 27200                       | <b>2437</b>          |
| <b>DORV</b>                          | 0                        | 0                            | 0                          | 0                         | 0                        | 0                          | 3                            | 0                           | <b>0</b>             |
| <b>HLHS</b>                          | 0                        | 0                            | 0                          | 0                         | 0                        | 0                          | 3                            | 2                           | <b>0</b>             |
| <b>PA</b>                            | 0                        | 3                            | 0                          | 0                         | 1                        | 0                          | 1                            | 0                           | <b>1</b>             |
| <b>d-TGA</b>                         | 1                        | 3                            | 0                          | 1                         | 0                        | 0                          | 2                            | 0                           | <b>1</b>             |
| <b>TAPVC</b>                         | 0                        | 0                            | 2                          | 1                         | 1                        | 1                          | 0                            | 1                           | <b>0</b>             |
| <b>TRUNCUS</b>                       | 0                        | 0                            | 1                          | 2                         | 1                        | 0                          | 3                            | 0                           | <b>0</b>             |
| <b>TA</b>                            | 0                        | 0                            | 0                          | 0                         | 0                        | 0                          | 0                            | 1                           | <b>1</b>             |
| <b>AA/AS</b>                         | 0                        | 0                            | 0                          | 0                         | 0                        | 0                          | 1                            | 0                           | <b>0</b>             |
| <b>TOF</b>                           | 1                        | 1                            | 0                          | 2                         | 0                        | 0                          | 0                            | 0                           | <b>1</b>             |
| <b>AVSD</b>                          | 0                        | 0                            | 0                          | 1                         | 0                        | 0                          | 1                            | 0                           | <b>0</b>             |
| <b>CoA</b>                           | 1                        | 2                            | 0                          | 0                         | 0                        | 1                          | 1                            | 3                           | <b>0</b>             |
| <b>PS</b>                            | 1                        | 0                            | 0                          | 0                         | 0                        | 0                          | 1                            | 0                           | <b>0</b>             |
| <b>TOTAL</b>                         | 4                        | 9                            | 3                          | 7                         | 3                        | 2                          | 16                           | 7                           | <b>4</b>             |



**Table – 13**  
**PULSE OXIMETRY SCREENING STUDIES FOR CRITICAL**  
**CONGENITAL HEART DISEASE (CCHD)**

| <b>First author</b>     | <b>No of babies screened</b> | <b>Age at screening (h)</b> | <b>Probe location</b> | <b>Cut off normal</b> | <b>False positive</b> | <b>False positive rate(%)</b> | <b>True positive</b> |
|-------------------------|------------------------------|-----------------------------|-----------------------|-----------------------|-----------------------|-------------------------------|----------------------|
| Hoke <sup>73</sup>      | 2876                         | <24                         | H&F                   | ≥92                   | 53                    | 1.84                          | 4                    |
| Richmond <sup>10</sup>  | 5626                         | 11.7                        | F                     | ≥95                   | 51                    | 0.91                          | 9                    |
| Koppel <sup>11</sup>    | 11281                        | 72                          | F                     | ≥96                   | 1                     | 0.01                          | 3                    |
| Reich <sup>26</sup>     | 2114                         | >24                         | H&F                   | ≥95                   | 2                     | 0.09                          | 1                    |
| Bakr <sup>37</sup>      | 5211                         | 31.7                        | H&F                   | ≥94                   | 1                     | 0.02                          | 3                    |
| Rosati <sup>74</sup>    | 5292                         | 72                          | F                     | ≥96                   | 1                     | 0.02                          | 2                    |
| Arlettaz <sup>75</sup>  | 3262                         | 8                           | F                     | ≥95                   | 7                     | 0.21                          | 17                   |
| Kawalec <sup>53</sup>   | 27200                        | 26                          | F                     | ≥95                   | 13                    | 0.05                          | 7                    |
| Meberg <sup>104</sup>   | 50008                        | 6                           | F                     | ≥95                   | 324                   | 0.65                          | 43                   |
| Sendelbach <sup>6</sup> | 10976                        | 4                           | F                     | ≥96                   | 636                   | 4.5                           | 0                    |
| <b>Our study</b>        | <b>2437</b>                  | <b>36</b>                   | <b>F</b>              | <b>≥95</b>            | <b>7</b>              | <b>0.28</b>                   | <b>4</b>             |

## **EFFECTIVENESS OF CLINICAL EXAMINATION SCREENING**

In our study 2437 healthy new born babies were screened. Out of the 2437 babies 36 had heart murmur. The prevalence of murmur was 14.8 per 1000 of normal new borns during the period of study. The reported prevalence of heart murmur in neonate varies from 6 per 1000 to 42 per 1000. These variations may be due to the examiner's skills and experience, the timing and frequency of examination, the conditions under which examination takes place and the size of population studied<sup>24</sup>.

All those babies with murmur underwent echocardiography. CHD were detected in 25(69.4%) babies and 11 (30.6%) babies had structurally normal heart. Out of the 25 babies with CHD, 10 (40%) babies had VSD which was the common lesion.

**Table - 14**

**COMPARISON OF OUR STUDY WITH OTHER CARDIAC  
CLINICAL EXAMINATION SCREENING STUDIES**

| <b>First author</b>           | <b>No of babies screened</b> | <b>No of babies with murmur</b> | <b>Prevalence of murmur per 1000 babies</b> | <b>Babies with CHD confirmed by ECHO</b> | <b>Babies with normal heart confirmed by ECHO</b> |
|-------------------------------|------------------------------|---------------------------------|---|--|---|
| <b>BANSAL<sup>27</sup></b>    | 2603                         | 62                              | 23.8  | 46(74.2%)                                | 16(25.8%)   |
| <b>LARDHI<sup>25</sup></b>    | 6333                         | 87                              | 13.7  | 61(70.1%)                                | 26(29.9%)   |
| <b>MEHRDED<sup>35</sup></b>   | 2928                         | 91                              | 31.1  | 47(51.6%)                                | 44(48.4%)   |
| <b>AINSWORTH<sup>24</sup></b> | 7204                         | 46                              | 6.3   | 25(54.3%)                                | 21(45.7%)   |
| <b>OUR STUDY</b>              | <b>2437</b>                  | <b>36</b>                       | <b>14.8</b>                                 | <b>25(69.4%)</b>                         | <b>11(30.6%)</b>                                  |

**Table – 15**

| <b>FIRST AUTHOR</b>           | <b>NO OF BABIES WITH CHD</b> | <b>NO BABIES WITH VSD</b> |
|-------------------------------|------------------------------|---------------------------|
| <b>BANSAL<sup>27</sup></b>    | 46                           | 19(41.3%)                 |
| <b>LARDHI<sup>25</sup></b>    | 61                           | 25(40.9%)                 |
| <b>MEHRDED<sup>35</sup></b>   | 47                           | 16(34.0%)                 |
| <b>AINSWORTH<sup>24</sup></b> | 25                           | 15(60.0%)                 |
| <b>OUR STUDY</b>              | <b>25</b>                    | <b>10(40.0%)</b>          |

Tanner et al observed innocent murmur in 44(48.4%) and congenital structural heart defects in (51.6%) newborns<sup>38</sup>. Rein et al found that 24% of heart murmurs in neonates were innocent.<sup>61</sup> Another study has shown that the prevalence of heart murmur is 13.7 per 1000 neonates. If a murmur is heard, there is a 42.5% chance of presence of an underlying cardiac malformation.<sup>86</sup> Yet another study stated that 84% of heart murmurs in neonates were caused by heart diseases and only 16% were innocent and urged subsequent echocardiography.<sup>21</sup> Many types of congenital heart disease may be associated with an asymptomatic murmur, the most common being ventricular septal defect (VSD)<sup>27,25,35</sup> Our study also showed similar results. We found that 30.6% of heart murmurs were innocent and 69.4% of heart murmurs had underlying CHD ; among them VSD was the most common lesion (40%).

### **EFFECTIVENESS OF COMBINED [PULSE OXIMETRY+ CLINICAL EXAMINATION] SCREENING**

In this study, we evaluated the efficacy of combining pulse oximetry with clinical examination in screening for CHD. In our study, CHD was detected in 37 babies (20 babies by clinical examination screening +12 babies by pulse oximeter screening +5 babies were positive for both screening test). Out of them 25 babies had murmur and 12 babies had no significant positive clinical examination including

murmur, but had abnormal pulse oximetry. Of the 12 babies 3 babies had cyanotic congenital heart disease.

Our study showed that pulse oximetry can detect CHD in asymptomatic newborns which was missed by routine clinical examination especially life threatening cyanotic congenital heart disease. Clinical examination also picked up another group of cases that were missed by pulse oximetry. Most of the acyanotic heart diseases were detected by means of a murmur. So the combined approach had an additive effect and resulted in more efficient screening.

## CONCLUSION

- This study indicates that pulse oximetry is a noninvasive, reliable and useful screening tool for an early detection of congenital heart diseases especially cyanotic congenital heart diseases.
- The normal oxygen saturation (negative pulse oximetry screening) does not rule out CHD especially acyanotic congenital heart disease.
- The prevalence of murmurs detected at routine examination of neonates is 1.48%.
- About 69.4% murmurs were due to an underlying cardiovascular malformation. So detection of a cardiac murmur may be a clue to the presence of an underlying heart disease particularly in asymptomatic newborn.
- The absence of a murmur does not exclude serious heart disease.
- This study concludes that the combination of pulse oximetry and clinical examination results in early detection of CHD. Pulse oximetry has an additive effect and results in more efficient screening.
- This study suggests that combined screening (pulse oximetry + cardiac clinical examination) should be used as a screening method for detection of CHD.

## LIMITATIONS

- Small sample size
- For all babies, a follow up evaluation was not performed.
- Sensitivity and specificity could not be calculated since echocardiography was not performed on screening negative babies to know the true negative and false negative cases.

## **RECOMMENDATIONS**

This study recommends pulse oximetry to be added to routine clinical examination as a screening method for early detection of CHD.



## BIBLIOGRAPHY

1. Hoffman JIE, Kaplan S. The incidence of congenital heart disease. *JACC*. 2002;39:18 90-900.
2. Abu-Harb M, Hey E, Wren C. Death in infancy from unrecognized congenital heart disease. *Arch Dis Child*. 1994;71: 3-7.
3. Koenig P, Ziyad MH, Zimmerman F. *Essential Pediatric Cardiology*. NewYork: The McGraw-Hill Companies; 2004.
4. Sunnegårdh J. *Barnkardiologi-en översikt*. Lund: Studentlitteratur; 2000.
5. Srivastava D, Baldwin HS. Molecular determinants of cardiac development. In: Allen HD, Gutgesell HG, Clark EB, Driscoll DJ, eds. *Moss and Adams' Heart Disease in infants, children, and adolescents including the fetus and young adult*. Vol 1. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001:1-20.
6. Sendelbach DM, Jackson GL, Lai SS, Fixler DE, Stehel EK, Engle WD. Pulse oximetry screening at 4 hours of age to detect critical congenital heart defects. *Pediatrics*. Oct 2008;122(4):e 815-820.
7. Pradat P, Francannet C, Harris JA, Robert E. The epidemiology of cardiovascular defects, part I: a study based on data from three large registries of congenital malformations. *Pediatr Cardiol*. May-Jun 2003;24(3):195-221.
8. Ferencz C, Neill CA. Cardiovascular malformations: prevalence at livebirth. In: Freedom RM, Benson LN, Smallhorn JF, eds. *Neonatal Heart Disease*. London: Springer-Verlag; 1992:19-29.

9. Reich JD, Connolly B, Bradley G, Littman S, Koeppel W, Lewycky P, Liske M. Reliability of a Single Pulse Oximetry Reading as a Screening Test for Congenital Heart Disease in Otherwise Asymptomatic Newborn Infants: The Importance of Human Factors. *Pediatr Cardiol.* Oct 12 2007.
10. Richmond S, Reay G, Abu Harb M. Routine pulse oximetry in the asymptomatic newborn. *Arch Dis Child Fetal Neonatal Ed.* Sep 2002;87(2):F83-88.
11. Koppel RI, Druschel CM, Carter T, Goldberg BE, Mehta PN, Talwar R, Bierman FZ. Effectiveness of pulse oximetry screening for congenital heart disease in asymptomatic newborns. *Pediatrics.* Mar 2003;111(3):451-455.
12. Wren C, Reinhardt Z, Khawaja K. Twenty-year trends in diagnosis of lifethreatening neonatal cardiovascular malformations. *Arch Dis Child Fetal Neonatal Ed.* Jan 2008;93(1):F33-35.
13. Boneva RS, Botto LD, Moore CA, Yang Q, Correa A, Erickson JD. Mortality associated with congenital heart defects in the United States: trends and racial disparities, 1979 –1997. *Circulation.* 2001;103:2376 – 2381.
14. Keuhl KS, Loffredo CA, Ferencz C. Failure to diagnosed congenital heart disease in infancy. *Pediatrics.* 1999; 103:743-747.
15. Byard RW, Moore L (1991) Total anomalous pulmonary venous drainage and sudden death in infancy. *Forens Sci Intl* 51:197–202

16. Grech V (2000) Diagnostic and interventional trends in tetralogy of Fallot and transposition of the great arteries in a population-based study. *Pediatr Cardiol* 21:368–373
17. Silove ED (1994) Assessment and management of congenital heart in the newborn by the district paediatrician. *Arch Dis Child* 70:F71–F74
18. Varan B, Tokel K, Yilmaz G (1999) Malnutrition and growth failure in cyanotic and acyanotic congenital heart disease with and without pulmonary hypertension. *Arch Dis Child* 81:49–52
19. Archer N (1999) Cardiovascular disease. In: Rennie J, Robertson N (eds) *Textbook of neonatology*, 3rd edn. Churchill Livingstone, Edinburgh, pp 673–713
20. Danford DA (1995) Cost-effectiveness of echocardiography for evaluation of children with murmurs. *Echocardiography* 12:153–162
21. Du ZD, Roguin N, Barak M (1997) Clinical and echocardiographic evaluation of neonates with heart murmurs. *Acta Paediatr* 86:752–756
22. Frommelt MA (2004) Differential diagnosis and approach to a heart murmur in term infants. *Pediatr Clin N Am* 51:1023–1032
23. Wren C, Richmond S, Donaldson L (1999) Presentation of congenital heart disease in infancy: implications for routine examination. *Arch Dis Child Fetal Neonatal Ed.* 80:F49–F53
24. Ainsworth SB, Wyllie JP, Wren C (1999) Prevalence and clinical significance of cardiac murmurs in neonates. *Arch Dis Child Fetal Neonatal Ed* 80:F43–F45

25. Amer Abdullah Lardhi. Prevalence and clinical significance of heart murmurs detected in routine neonatal examination. *Journal of the Saudi Heart Association* Volume 22, Issue 1 , Pages 25-27, January 2010
26. Reich JD, Miller S, Brogdon B, et al. (2003) The use of pulse oximetry to detect congenital heart disease. *Pediatrics* 111: 451–455
27. Bansal M, Jain H. Cardiac murmur in neonates. *Indian Pediatr.* 2005;42:397–398
28. Allan L, Hornberger LK, Sharland G. *Textbook of Fetal Cardiology*. London: Greenwich Medical Media; 2000.
29. McLachlan J. *Medical Embryology*. Wokingham: Addison-Wesley; 1994.
30. Henderson D, Hutson MR, Kirby ML. Embryos, Genes and Birth Defects. In: Ferretti P, Chopp A, Tickle C, Moore G, eds. 2 ed. Chichester: John Wiley & Sons; 2006:342-363.
31. Rose V, Clark E. Etiology of congenital heart disease. In: Freedom RM, Benson LN, Smallhorn JF, eds. *Neonatal Heart Disease*. London: Springer- Verlag; 1992:3-17.
32. Liske MR, Greeley CS, Law DJ, Reich JD, Morrow WR, Baldwin HS, Graham TP, Strauss AW, Kavanaugh-McHugh AL, Walsh WF. Report of the Tennessee Task Force on Screening Newborn Infants for Critical Congenital Heart Disease. *Pediatrics*. Oct 2006;118(4):e1250-1256.
33. Rosati E, Chitano G, Dipaola L, De Felice C, Latini G. Indications and limitations for a neonatal pulse oximetry screening of critical congenital heart disease. *J Perinat Med*. 2005;33(5):455-457.

34. Mellander M, Sunnegardh J. Failure to diagnose critical heart malformations in newborns before discharge--an increasing problem? *Acta Paediatr.* Apr 2006;95(4):407-413.
35. Mehrdad Mirzarahimi. Heart Murmur in Neonates: How Often Is It Caused by Congenital Heart Disease? *Iran J Pediatr* Mar 2011; Vol 21 (No 1), Pp: 103-106.
36. Abu-Harb M, Wyllie J, Hey E. et al. Presentation of obstructive left heart malformations in infancy. *Arch Dis Child Fetal Neonatal Ed* 1994. 71 179–183.
37. Bakr A F, Habib H S. Combining pulse oximetry and clinical examination in screening for congenital heart disease. *Pediatr Cardiol* 2005. 26 832–835
38. Tanner K, Sabrine N, Wren C. Cardiovascular malformations among preterm infants. *Pediatrics* 2005;116(6):e 833-8.
39. Ward K E, Pryor R W, Matson J R. et al Delayed detection of coarctation in infancy : implications for timing of new born follow up. *Paediatrics* 1990, 86 972, pg 976.
40. Garne E, Stoll C, Clementi M. et al Evaluation of prenatal diagnosis of heart diseases by ultrasound: experience from 20 European countries. *Ultrasound Obstet Gynecol* 2001. 17 386–391.
41. Allan LD. A practical approach to fetal heart scanning. *Semin Perinatol.* 2000;24:324 –330
42. Acharya G, Sitras V, Maltau JM, Dahl LB, Kaaresen PI, Hanssen TA, Lunde P. Major congenital heart disease in Northern Norway:

shortcomings of pre- and postnatal diagnosis. *Acta Obstet Gynecol Scand.* 2004;83:1124–1129

43. Hunter S, Heads A, Wyllie J, Robson S. Prenatal diagnosis of congenital heart disease in the northern region of England: benefits of a training programme for obstetric ultrasonographers. *Heart.* 2000;84:294–298
44. Klein SK, Cans C, Robert E, Jouk PS. Efficacy of routine fetal ultrasound screening for congenital heart disease in Ise`re County, France. *Prenat Diagn.* 1999;19:318–322
45. Randall P, Brealey S, Hahn S, Khan KS, Parsons JM. Accuracy of fetal echocardiography in the routine detection of congenital heart disease among unselected and low risk populations: a systematic review. *BJOG.* 2005;112:24–30
46. Tegnander E, Williams W, Johansen OJ, Blaas HG, Eik-Nes SH. Prenatal detection of heart defects in a non-selected population of 30,149 fetuses: detection rates and outcome. *Ultrasound Obstet Gynecol.* 2006;27:252–265
47. Westin M, Saltvedt S, Bergman G, Kublickas M, Almstro`m H, Grunewald C, Valentin L. Routine ultrasound examination at 12 or 18 gestational weeks for prenatal detection of major congenital heart malformations? A randomised controlled trial comprising 36,299 fetuses. *BJOG.* 2006;113:675–682
48. Queisser-Luft A, Stopfkuchen H, Stolz G, Schlaefer K, Merz E. Prenatal diagnosis of major malformations: quality control of routine ultrasound examinations based on a five-year study of 20,248 newborn fetuses and infants. *Prenat Diagn.* 1998;18:567–576

49. Timor-Tritsch IE. As technology evolves, so should its application: shortcomings of the “18-week anatomy scan.” *J Ultrasound Med.* 2006;25:423–428
50. Bofill JA, Sharp GH. Obstetric sonography: who to scan, when to scan, and by whom. *Obstet Gynecol Clin North Am.* 1998;25:465–478
51. Forrester MB, Merz RD. Use of prenatal diagnostic procedures in pregnancies affected with birth defects, Hawaii, 1986 –2002. *Birth Defects Res A Clin Mol Teratol.* 2006;76:778 –780
52. Gavin NI, Adams EK, Hartmann KE, Benedict MB, Chireau M. Racial and ethnic disparities in the use of pregnancy-related health care among Medicaid pregnant women. *Matern Child Health J.* 2004;8:113–126
53. Kawalec W, Blaz W, Turska-Kmiec A, Zuk M, Helwich E, Tobota Z. Pulse oximetry as a population screening test in detection of critical congenital heart disease in presymptomatic newborns: Polish multicentre study. *Cardiol Young.* 2006;16(suppl 2):25. Abstract
54. Danford DA. Sorting through the haystack: decision analysis and the search for heart disease among children with murmur. *J Pediatr.* 2002;141:465–467
55. Griebisch I, Knowles RL, Brown J, Bull C, Wren C, Dezateux CA. Comparing the clinical and economic effects of clinical examination, pulse oximetry, and echocardiography in newborn screening for congenital heart defects: a probabilistic cost-effectiveness model and value of information analysis. *Int J Technol Assess Health Care.* 2007;23:192–204

56. Gidding SS, Anisman P. What pediatric residents should learn (or what pediatricians should know) about congenital heart disease. *Pediatr Cardiol*. 2003;24:418–423.
57. Patton C, Hey E. How effectively can clinical examination pick up congenital heart disease at birth? *Arch Dis Child Fetal Neonatal Ed*. 2006;91:F263–F267.
58. Lundsgaard C, Van Slyke DD. Cyanosis. *Medicine*. 1923;2:1–76
59. Lees MH. Cyanosis of the newborn infant: recognition and clinical evaluation. *J Pediatr*. 1970;77:484–498
60. Schmitt HJ, Schuetz WH, Proeschel PA, Jaklin C (1993) Accuracy of pulse oximetry in children with cyanotic congenital heart disease. *J Cardiothorac Vasc Anesth* 7:61–65
61. Rein AJ, Omokhodion SI, Nir A. Significance of a cardiac murmur as the sole clinical sign in the newborn. *Clin Pediatr (Phila)* 2000;39(9):511-20
62. O'Donnell CP, Kamlin CO, Davis PG, Carlin JB, Morley CJ. Clinical assessment of infant colour at delivery. *Arch Dis Child Fetal Neonatal Ed*. 2007;92:F465–F467
63. Katzman GH. The newborn's SpO<sub>2</sub>: a routine vital sign whose time has come? *Pediatrics*. 1995;95:161–162.
64. Toth B, Becker A, Seelbach-Gobel B. Oxygen saturation in healthy Newborn infants immediately after birth measured by pulse oximetry. *Arch Gynecol Obstet* 2002. 266 105–107.
65. Gidding SS (1992) Pulse oximetry in cyanotic congenital heart disease. *Am J Cardiol* 70:391–392



66. O'Brien L M, Stebbens V A, Poets C F. et al Oxygen saturation during the first 24 hours of life. *Arch Dis Child Fetal Neonatal Ed* 2000. 83 F35–F38.
67. Poets CF. Assessing oxygenation in healthy infants. *J Pediatr*. 1999;135:541–543
68. Poets CF, Stebbens VA, Lang JA, O'Brien LM, Boon AW, Southall DP. Arterial oxygen saturation in healthy term neonates. *Eur J Pediatr*. 1996;155:219 –223
69. Levesque BM, Pollack P, Griffin BE, Nielsen HC. Pulse oximetry: what's normal in the newborn nursery? *Pediatr Pulmonol*. 2000;30:406-412.
70. Byrne B J, Donohue P K, Bawa R D. et al Oxygen saturation as a screening test for critical congenital heart disease [abstract]. *Pediatr Res* 1995. 37(Suppl)198A.
71. Thangaratinam S, Daniels J, Ewer AK, Zamora J, Khan KS. Accuracy of pulse oximetry in screening for congenital heart disease in asymptomatic newborns: a systematic review. *Arch Dis Child Fetal Neonatal Ed*. 2007;92:F176 –F180
72. Niermeyer S, Shaffer EM, Thilo E, Corbin C, Moore LG. Arterial oxygenation and pulmonary arterial pressure in healthy neonates and infants at high altitude. *J Pediatr*. 1993;123:767–772
73. Hoke T R, Donohue P K, Bawa R D. et al Oxygen saturation as a screening test for critical congenital heart disease: a preliminary study. *Pediatr Cardiol* 2002. 23 403–409.

74. Rosati E, Chitano G, Dipaola L. et al Indications and limitations for a neonatal pulse oximetry screening of critical congenital heart disease. *J Perinat Med* 2005. 33 455–457.
75. Arlettaz R, Bauschatz A S, Mönkhoff M. et al The contribution of pulse oximetry to the early detection of congenital heart disease in newborns. *Eur J Pediatr* 2006. 16 594–98.
76. Poets C F, Southall D P. Noninvasive monitoring of oxygenation in infants and children: Practical considerations and areas of concern. *Pediatrics* 1994. 93 737–746.
77. Mok JY, McLaughlin FJ, Pintar M, Hak H, Maro-Galvez R, Levison H. Transcutaneous monitoring of oxygenation: what is normal? *J Pediatr*. 1986;108:365–371
78. Hay WW Jr, Rodden DJ, Collins SM, Melara DL, Hale KA, Fashaw LM. Reliability of conventional and new pulse oximetry in neonatal patients. *J Perinatol*. 2002;22:360 –366
79. Hay WW Jr. Physiology of oxygenation and its relation to pulse oximetry in neonates. *J Perinatol*. 1987;7:309 –319
80. Severinghaus JW. History and recent developments in pulse oximetry. *Scand J Clin Lab Invest Suppl*. 1993;214:105–111
81. Barker SJ, Shah NK. Effects of motion on the performance of pulse oximeters in volunteers. *Anesthesiology*. 1996;85:774 –781
82. Clayton DG, Webb RK, Ralston AC, Duthie D, Runciman WB. Pulse oximeter probes: a comparison between finger, nose, ear and forehead probes under conditions of poor perfusion. *Anaesthesia*. 1991;46:260 –265

83. Poets CF, Stebbens VA. Detection of movement artifact in recorded pulse oximeter saturation. *Eur J Pediatr.* 1997;156:808–811
84. Gerstmann D, Berg R, Haskell R, Brower C, Wood K, Yoder B, Greenway L, Lassen G, Ogden R, Stoddard R, Minton S. Operational evaluation of pulse oximetry in NICU patients with arterial access. *J Perinatol.* 2003;23:378–383
85. Bickler PE, Feiner JR, Severinghaus JW. Effects of skin pigmentation on pulse oximeter accuracy at low saturation. *Anesthesiology.* 2005;102:715–719
86. Wu MH, Chen HC, Lu CW, et al. Prevalence of congenital heart disease at live birth in Taiwan. *J Pediatr* 2010;156(5):782-5.
87. Kamat V. Pulse Oximetry. *Indian J Anaesth.* 2002;46(4):261-268.
88. Barker SJ, Tremper KK. The effect of carbon monoxide inhalation on pulse oximetry and transcutaneous PO<sub>2</sub>. *Anesthesiology.* May 1987;66(5):677-679.
89. Salyer JW. Neonatal and pediatric pulse oximetry. *Respir Care.* Apr 2003;48(4):386-396; discussion 397-388
90. Sola A, Chow L, Rodigo M. Pulse oximetry in neonatal care in 2005. A comprehensive state of the art review. *An Pediatr* 2005;62:266 - 280.
91. Valmari P. Should pulse oximetry be used to screen for congenital heart disease? *Arch Dis Child Fetal Neonatal Ed.* May 2007;92(3):F219-224.
92. Chan MM, Chan MM, Chan ED. What is the effect of fingernail polish on pulse oximetry? *Chest.* Jun 2003;123(6):2163-2164.

93. Rubin AS. Nail polish color can effect pulse oximeter saturation. *Anesthesiology*. 1988;68:825.
94. Shah NK, Barker SJ, Hyatt J. Comparison of alarm conditions between new pulse oximeters during motion at normal and lower oxygen saturations [abstract]. *Anesthesiology*. 1995;83:A1067.
95. Barker SJ, Shah NK. The effects of motion on the performance of pulse oximeters in volunteers (revised publication). *Anesthesiology*. Jan 1997;86(1):101-108.
96. Barker SJ, Shah NK, Hyatt J. Pulse oximetry and motion artefact: a study of accuracy and reliability [abstract]. *Anesthesiology*. 1995;83:A450.
97. Petterson MT, Begnoche VL, Graybeal JM. The effect of motion on pulse oximetry and its clinical significance. *Anesth Analg*. Dec 2007;105(6 Suppl):S78-84.
98. Trivedi NS, Ghouri AF, Shah NK, Lai E, Barker SJ. Effects of motion, ambient light, and hypoperfusion on pulse oximeter function. *J Clin Anesth*. May 1997;9(3):179-183.
99. Giuliano KK, Higgins TL. New-generation pulse oximetry in the care of critically ill patients. *Am J Crit Care*. Jan 2005;14(1):26-37; quiz 38-29
100. Sahni R, Gupta A, Ohira-Kist K, Rosen TS. Motion resistant pulse oximetry in neonates. *Arch Dis Child Fetal Neonatal Ed*. Nov 2003;88(6):F505-508.
101. Giuliano KK, Liu LM. Knowledge of Pulse Oximetry Among Critical Care Nurses. *Dimensions of Critical Care Nurses*. 2006;25(1):44-49.

102. Gnanalingham M G, Mehta B M, Siverajan M. et al Pulse oximetry as a screening test in neonates. Arch Dis Child 2001. 84(Suppl I)A35.
103. Feiner JR, Severinghaus JW, Bickler PE. Dark skin decreases the accuracy of pulse oximeters at low oxygen saturation: the effects of oximeter probe type and gender. Anesth Analg. Dec 2007;105(6 Suppl):S18-23, tables of contents.
104. Meberg A, Brun C. Pulse oximetry screening for congenital heart defects in newborn infants. (Abstract) of XIX Nordic Congress of Perinatal Medicine. 19–21 May 2005, Lund, Sweden.
105. Mahle WT, Newburger JW, Matherne GP, Smith FC, Hoke TR, Koppel R, et al. Role of pulse oximetry in examining newborns for congenital heart disease. A scientific statement from the American Heart Association and American Academy of Pediatrics. Circulation.2009;120: 447-8.
106. Myung K.Park Pediatric cardiology for practitioners 5 th edition pages no.75-76
107. John P.Cloherty, Eric C.Eichenwald,Ann R.Stark manual of neonatal care 6<sup>th</sup> edition pages 387-393
108. de Wahl Granelli A, Wennergren M, et al. Impact of pulse oximetry screening on detection of duct dependent congenital heart disease:a Swedish prospective screening study in 39 821 newborns. BMJ 2009; 338: A3037.
109. Kliegman, Behrman, Jenson, Stanton. Nelson text book of paediatrics, volume-2 pages 1851-1856

## PROFORMA

S.NO:

BABY OF:

ADDRESS:

IP.NO:

MOTHER DETAILS:

| AGE(Y) | GRAVIDA | PARA | CONSANGUINITY | FAMILY H/O CHD | AN SCAN | INFECTION | DM  | DRUGS |
|--------|---------|------|---------------|----------------|---------|-----------|-----|-------|
|        |         |      |               | YES            | YES     | YES       | YES | YES   |
|        |         |      |               | NO             | NO      | NO        | NO  | NO    |

BABY DETAILS:

| MODE OF DELIVERY<br>N/LSCS/FORCEPS/BREECH | GESTATIONAL AGE<br>(TERM/PRETERM) | DATE OF<br>DELIVERY | TIME OF<br>DELIVERY | SEX<br>(M/F) | WT(KG) |
|---|-----------------------------------|---------------------|---------------------|--------------|--------|
|   |                                   |                     |                     |              |        |

SCREENING DETAILS:

| DATE OF SCREENING | TIME OF SCREENING | BABY AGE AT SCREENING |
|-------------------|-------------------|-----------------------|
| 1                 |                   |                       |
| 2                 |                   |                       |

**CLINICAL EXAMINATION SCREENING:**

|                           |                 |                  |                    |               |
|---------------------------|-----------------|------------------|--------------------|---------------|
| <b>CONGENITAL ANOMALY</b> | <b>CYANOSIS</b> | <b>TACHYPNEA</b> | <b>TACHYCARDIA</b> | <b>MURMUR</b> |
| YES/NO                    | YES/NO          | YES/NO           | YES/NO             | YES/NO        |

|                           |                           |
|---------------------------|---------------------------|
| <b>SCREENING POSITIVE</b> | <b>SCREENING NEGATIVE</b> |
|---------------------------|---------------------------|

**PULSE OXIMETRY SCREENING:**

|                                 |       |     |   |       |     |
|---------------------------------|-------|-----|---|-------|-----|
| <b>1. OXYGEN SATURATION (%)</b> |       |     | <b>2. OXYGEN SATURATION(%)<br/>AFTER 6 HOURS IF NECESSARY</b> |       |     |
| ≥95                             | 90-94 | <90 | ≥95   | 90-94 | <90 |

|                           |                           |
|---------------------------|---------------------------|
| <b>SCREENING POSITIVE</b> | <b>SCREENING NEGATIVE</b> |
|---------------------------|---------------------------|

**ECHOCARDIOGRAPHY RESULTS:**

|               |                 |
|---------------|-----------------|
| <b>NORMAL</b> | <b>ABNORMAL</b> |
|---------------|-----------------|

**ECHOCARDIOGRAPHY DIAGNOSIS:**

## MASTER CHART

| S.NO | NAME OF THE BABY | MOTHER DETAILS |                |         |    |           |                | BABY DETAILS     |                 |     |         | CLINICAL EXAMINATION |           |          |        |                    |     | PULSE OXIMETER READING |                           |     | ECHO RESULT |
|------|------------------|----------------|----------------|---------|----|-----------|----------------|------------------|-----------------|-----|---------|----------------------|-----------|----------|--------|--------------------|-----|------------------------|---------------------------|-----|-------------|
|      |                  | CONSAINGUINITY | FAMILY H/O CHD | AN SCAN | DM | INFECTION | DRUGS EXPOSURE | MODE OF DELIVERY | GESTATIONAL AGE | SEX | WT (KG) | TACHYCARDIA          | TACHYPNEA | CYANOSIS | MURMUR | CONGENITAL ANOMALY | P/N | TIME (HOURS)           | RT FOOT (O2 SATURATION %) | P/N |             |
| 1    | B/O Vijaya       | NCM            | A              | N       | A  | A         | A              | N                | T               | F   | 2.8     | A                    | A         | A        | -      | A                  | N   | 30                     | 88                        | P   | TRI ATRESIA |
| 2    | B/O Jones        | NCM            | A              | N       | A  | A         | A              | L                | T               | M   | 2.8     | A                    | A         | A        | -      | A                  | N   | 38                     | 85                        | P   | d-TGA       |
| 3    | B/O Chellakani   | CM             | A              | N       | A  | A         | A              | L                | T               | F   | 2.2     | A                    | A         | A        | -      | A                  | N   | 32                     | 83                        | P   | PULATRESIA  |
| 4    | B/O Jothi        | CM             | A              | N       | A  | A         | A              | N                | T               | F   | 2.0     | A                    | A         | A        | +      | A                  | P   | 37                     | 91                        | P   | TOF         |
| 5    | B/O Isakiselvi   | CM             | A              | N       | A  | A         | A              | L                | T               | F   | 2.7     | A                    | A         | A        | +      | A                  | P   | 38                     | 97                        | N   | VSD         |
| 6    | B/O Leelavathi   | CM             | A              | N       | A  | A         | A              | N                | T               | M   | 2.4     | A                    | A         | A        | +      | A                  | P   | 34                     | 98                        | N   | VSD         |
| 7    | B/O Panchu       | NCM            | A              | N       | A  | A         | A              | L                | T               | F   | 2.5     | A                    | A         | A        | +      | A                  | P   | 32                     | 97                        | N   | VSD         |
| 8    | B/O Jenagai mari | NCM            | A              | N       | A  | A         | A              | L                | T               | F   | 3.0     | A                    | A         | A        | +      | A                  | P   | 29                     | 95                        | N   | VSD         |
| 9    | B/O Sudha        | NCM            | A              | N       | A  | A         | A              | L                | T               | M   | 2.6     | A                    | A         | A        | +      | A                  | P   | 38                     | 96                        | N   | VSD         |
| 10   | B/O Jeyalaksmi   | NCM            | A              | N       | A  | A         | A              | N                | T               | M   | 3.4     | A                    | A         | A        | +      | A                  | P   | 40                     | 98                        | N   | VSD         |
| 11   | B/O Jansirani    | CM             | A              | N       | A  | A         | A              | N                | T               | M   | 3.2     | A                    | A         | A        | +      | A                  | P   | 38                     | 99                        | N   | VSD         |
| 12   | B/O Karthiga     | NCM            | A              | N       | A  | A         | A              | N                | T               | F   | 2.4     | A                    | A         | A        | +      | A                  | P   | 35                     | 96                        | N   | VSD         |
| 13   | B/O Sivasakthi   | NCM            | A              | N       | A  | A         | A              | L                | T               | M   | 2.8     | A                    | A         | A        | +      | A                  | P   | 38                     | 98                        | N   | VSD         |
| 14   | B/O Mareeswari   | CM             | A              | N       | A  | A         | A              | L                | T               | M   | 2.3     | A                    | A         | A        | +      | A                  | P   | 30                     | 97                        | N   | VSD         |
| 15   | B/O Chinaponnu   | NCM            | A              | N       | A  | A         | A              | L                | T               | F   | 3.0     | A                    | A         | A        | +      | A                  | P   | 37                     | 97                        | N   | L-ASD       |
| 16   | B/O Thenmozhi    | NCM            | A              | N       | A  | A         | A              | N                | T               | F   | 3.8     | A                    | A         | A        | +      | A                  | P   | 36                     | 96                        | N   | L-ASD       |
| 17   | B/OSudha         | NCM            | A              | N       | A  | A         | A              | N                | T               | F   | 2.7     | A                    | A         | A        | +      | A                  | P   | 31                     | 93                        | P   | ASD(OP)     |
| 18   | B/O Ramya        | CM             | A              | N       | A  | A         | A              | N                | T               | F   | 2.4     | A                    | A         | A        | +      | A                  | P   | 38                     | 98                        | N   | DEXTROCAR   |
| 19   | B/O Pothumponnu  | NCM            | A              | N       | A  | A         | A              | L                | T               | M   | 2.3     | A                    | A         | A        | +      | A                  | P   | 37                     | 96                        | N   | S-ASD       |



|    |                   |     |   |   |   |   |   |   |   |   |     |   |   |   |   |   |   |    |    |   |       |
|----|-------------------|-----|---|---|---|---|---|---|---|---|-----|---|---|---|---|---|---|----|----|---|-------|
| 20 | B/O Muthulakshmi  | NCM | A | N | A | A | A | N | T | M | 2.8 | A | A | A | + | A | P | 35 | 96 | N | S-ASD |
| 21 | B/O Shahirabanu   | CM  | A | N | A | A | A | L | T | F | 2.6 | A | A | A | + | A | P | 30 | 95 | N | S-ASD |
| 22 | B/O Periyatchi    | NCM | A | N | A | A | A | L | T | M | 3.1 | A | A | A | - | A | N | 32 | 94 | P | S-ASD |
| 23 | B/O Lalitha       | NCM | A | N | A | A | A | N | T | F | 3.7 | A | A | A | - | A | N | 30 | 94 | P | S-ASD |
| 24 | B/O Kowsalya      | NCM | A | N | A | A | A | N | T | F | 3.3 | A | A | A | - | A | N | 32 | 94 | P | S-ASD |
| 25 | B/O Natchiammal   | CM  | A | N | A | A | A | N | T | F | 2.9 | A | A | A | - | A | N | 29 | 94 | P | S-ASD |
| 26 | B/O Amsavalli     | NCM | A | N | A | A | A | N | T | M | 2.7 | A | A | A | + | A | P | 38 | 97 | N | S-PDA |
| 27 | B/O Hemalatha     | NCM | A | N | A | A | A | N | T | F | 2.5 | A | A | A | + | A | P | 35 | 97 | N | S-PDA |
| 28 | B/O Kathijabanu   | NCM | A | N | A | A | A | L | T | M | 2.5 | A | A | A | + | A | P | 39 | 96 | N | S-PDA |
| 29 | B/O Chithra       | CM  | A | N | A | A | A | N | T | F | 3.0 | A | A | A | + | A | P | 35 | 97 | N | S-PDA |
| 30 | B/O Jeevitha      | CM  | A | N | A | A | A | L | T | M | 2.8 | A | A | A | - | A | N | 31 | 94 | P | S-PDA |
| 31 | B/O Nishanthini   | NCM | A | N | A | A | A | N | T | F | 2.2 | A | A | A | - | A | N | 30 | 94 | P | S-PDA |
| 32 | B/O Selvamani     | NCM | A | N | A | A | A | L | T | M | 2.5 | A | A | A | - | A | N | 26 | 94 | P | S-PDA |
| 33 | B/O Santhi        | CM  | A | N | A | A | A | L | T | M | 2.9 | A | A | A | - | A | N | 29 | 94 | P | S-PDA |
| 34 | B/O Lalitha       | NCM | A | N | A | A | A | N | T | F | 3.4 | A | A | A | - | A | N | 26 | 94 | P | S-PDA |
| 35 | B/O Pandiammal    | NCM | A | N | A | A | A | N | T | M | 2.7 | A | A | A | + | A | P | 28 | 94 | P | S-PDA |
| 36 | B/O Murugayee     | NCM | A | N | A | A | A | N | T | F | 2.4 | A | A | A | + | A | P | 25 | 94 | P | S-PDA |
| 37 | B/O Devika        | NCM | A | N | A | A | A | L | T | F | 2.8 | A | A | A | + | A | P | 29 | 94 | P | S-PDA |
| 38 | B/O Muneeswari    | NCM | A | N | A | A | A | L | T | M | 2.9 | A | A | A | + | A | P | 30 | 98 | N | NS    |
| 39 | B/O Palanichithra | CM  | A | N | A | A | A | N | T | M | 2.8 | A | A | A | + | A | P | 32 | 95 | N | NS    |
| 40 | B/O Shanthi       | NCM | A | N | A | A | A | N | T | M | 2.2 | A | A | A | + | A | P | 31 | 97 | N | NS    |
| 41 | B/O Sudha         | NCM | A | N | A | A | A | L | T | F | 3.3 | A | A | A | + | A | P | 30 | 96 | N | NS    |
| 42 | B/O Jenifer       | NCM | A | N | A | A | A | L | T | M | 2.4 | A | A | A | + | A | P | 31 | 98 | N | NS    |
| 43 | B/O Vidhya        | NCM | A | N | A | A | A | N | T | M | 2.7 | A | A | A | + | A | P | 36 | 97 | N | NS    |
| 44 | B/O Devi          | CM  | A | N | A | A | A | N | T | M | 3.4 | A | A | A | + | A | P | 32 | 96 | N | NS    |
| 45 | B/O Chithra       | NCM | A | N | A | A | A | N | T | M | 2.9 | A | A | A | + | A | P | 29 | 97 | N | NS    |
| 46 | B/O Jeyanthi      | CM  | A | N | A | A | A | L | T | F | 2.7 | A | A | A | + | A | P | 31 | 97 | N | NS    |
| 47 | B/O Saranya       | NCM | A | N | A | A | A | N | T | F | 2.6 | A | A | A | + | A | P | 33 | 98 | N | NS    |
| 48 | B/O Selvi         | NCM | A | N | A | A | A | N | T | F | 2.7 | A | A | A | + | A | P | 35 | 98 | N | NS    |
| 49 | B/O Chinaponnu    | CM  | A | N | A | A | A | L | T | M | 2.5 | A | A | A | - | A | N | 29 | 94 | P | NS    |
| 50 | B/O Muthumari     | NCM | A | N | A | A | A | L | T | F | 2.8 | A | A | A | - | A | N | 30 | 94 | P | NS    |

|    |               |     |   |   |   |   |   |   |   |   |     |   |   |   |   |   |   |    |    |   |    |
|----|---------------|-----|---|---|---|---|---|---|---|---|-----|---|---|---|---|---|---|----|----|---|----|
| 51 | B/O Kavitha   | NCM | A | N | A | A | A | N | T | F | 2.6 | A | A | A | - | A | N | 28 | 94 | P | NS |
| 52 | B/O Alagu     | NCM | A | N | A | A | A | N | T | M | 2.4 | A | A | A | - | A | N | 31 | 94 | P | NS |
| 53 | B/O Muthukili | CM  | A | N | A | A | A | N | T | F | 2.6 | A | A | A | - | A | N | 30 | 94 | P | NS |
| 54 | B/O Jeyakodi  | NCM | A | N | A | A | A | L | T | F | 2.9 | A | A | A | - | A | N | 29 | 94 | P | NS |
| 55 | B/O Parimalam | NCM | A | N | A | A | A | N | T | M | 3.1 | A | A | A | - | A | N | 32 | 94 | P | NS |

[CM-consanguineous marriage, NCM-non consanguineous marriage, A-absent, N- natural labor, L-LSCS, T-term, M-male, F-female, + present, - negative, NS-normal study, S-small, L-large, P- Positive Screening, N-Negative Screening]

## **ABBREVIATIONS**

|                   |   |
|-------------------|---|
| CHD               | Congenital Heart Disease                |
| CCHD              | Critical Congenital Heart Disease       |
| CHF               | Congestive Heart Failure                |
| COHb              | Carboxy Haemoglobin                     |
| Hb                | Haemoglobin                             |
| RHb               | Reduced Haemoglobin or Deoxyhaemoglobin |
| IR                | Infra-Red                               |
| LED               | Light Emission Diode                    |
| MetHb             | Methaemoglobin                          |
| O <sub>2</sub> Hb | Oxyhaemoglobin                          |
| R                 | Red                                     |
| AS                | Aortic stenosis                         |
| AVSD              | Atrio ventricular Septal Defect         |
| ASD               | Atrial Septal Defect                    |
| CoA               | Coarctation of Aorta                    |
| DORV              | Double outlet right ventricle           |
| HLHS              | Hypoplastic Left Heart Syndrome         |
| IAA               | Interrupted Aortic Arch                 |
| PA                | Pulmonary Atresia                       |
| PDA               | Patent Ductus Arteriosus                |

|       |   |
|-------|---|
| PFO   | Patent Foramen Ovale                    |
| PS    | Pulmonary Stenosis                      |
| TA    | Tricuspid Atresia                       |
| TAPVR | Total Anomalous Pulmonary Venous Return |
| TGA   | Transposition of the Great Arteries     |
| TOF   | Tetralogy of Fallot                     |
| VSD   | Ventricular Septal Defect               |